

CANADIAN THESES ON MICROFICHE

THÈSES CANADIENNES SUR MICROFICHE



National Library of Canada
Collections Development Branch

Canadian Theses on
Microfiche Service

Ottawa, Canada
K1A 0N4

Bibliothèque nationale du Canada
Direction du développement des collections

Service des thèses canadiennes
sur microfiche

NOTICE

The quality of this microfiche is heavily dependent upon the quality of the original thesis submitted for microfilming. Every effort has been made to ensure the highest quality of reproduction possible.

If pages are missing, contact the university which granted the degree.

Some pages may have indistinct print especially if the original pages were typed with a poor typewriter ribbon or if the university sent us an inferior photocopy.

Previously copyrighted materials (journal articles, published tests, etc.) are not filmed.

Reproduction in full or in part of this film is governed by the Canadian Copyright Act, R.S.C. 1970, c. C-30. Please read the authorization forms which accompany this thesis.

**THIS DISSERTATION
HAS BEEN MICROFILMED
EXACTLY AS RECEIVED**

AVIS

La qualité de cette microfiche dépend grandement de la qualité de la thèse soumise au microfilmage. Nous avons tout fait pour assurer une qualité supérieure de reproduction.

S'il manque des pages, veuillez communiquer avec l'université qui a conféré le grade.

La qualité d'impression de certaines pages peut laisser à désirer, surtout si les pages originales ont été dactylographiées à l'aide d'un ruban usé ou si l'université nous a fait parvenir une photocopie de qualité inférieure.

Les documents qui font déjà l'objet d'un droit d'auteur (articles de revue, examens publiés, etc.) ne sont pas microfilmés.

La reproduction, même partielle, de ce microfilm est soumise à la Loi canadienne sur le droit d'auteur, SRC 1970, c. C-30. Veuillez prendre connaissance des formules d'autorisation qui accompagnent cette thèse.

**LA THÈSE A ÉTÉ
MICROFILMÉE TELLE QUE
NOUS L'AVONS REÇUE**



National Library
of Canada

Bibliothèque nationale
du Canada

Ottawa, Canada
K1A 0N4

TC -

67502

ISBN

0-315-19594-0

CANADIAN THESES ON MICROFICHE SERVICE - SERVICE DES THÈSES CANADIENNES SUR MICROFICHE

PERMISSION TO MICROFILM - AUTORISATION DE MICROFILMER

• Please print or type - Écrire en lettres moulées ou dactylographier

AUTHOR - AUTEUR

Full Name of Author - Nom complet de l'auteur

FRANCESCUTTI, LOUIS HUGO

Date of Birth - Date de naissance

DECEMBER 24, 1953

Canadian Citizen - Citoyen canadien

☒ Yes / Oui

☐ No / Non

Country of Birth - Lieu de naissance

CANADA

Permanent Address - Résidence fixe

444-85th AVENUE
CHOMEDÉY, LAVAL
QUEBEC H7W 2Z5

THESIS - THÈSE

Title of Thesis - Titre de la thèse

PRODUCTION AND CHARACTERIZATION OF
HEMOPDIETIC ANTIBODY-FACILITATED
CHIMERAS.

Degree for which thesis was presented
Grade pour lequel cette thèse fut présentée

PHD

Year this degree conferred
Année d'obtention de ce grade

1985

University - Université

UNIVERSITY OF ALBERTA

Name of Supervisor - Nom du directeur de thèse

DR. THOMAS G. WEGMANN

AUTHORIZATION - AUTORISATION

Permission is hereby granted to the NATIONAL LIBRARY OF CANADA to microfilm this thesis and to lend or sell copies of the film.

The author reserves other publication rights, and neither the thesis nor extensive extracts from it may be printed or otherwise reproduced without the author's written permission.

L'autorisation est, par la présente, accordée à la BIBLIOTHÈQUE NATIONALE DU CANADA de microfilmer cette thèse et de prêter ou de vendre des exemplaires du film.

L'auteur se réserve les autres droits de publication; ni la thèse ni de longs extraits de celle-ci ne doivent être imprimés ou autrement reproduits sans l'autorisation écrite de l'auteur.

ATTACH FORM TO THESIS - VEUILLEZ JOINDRE CE FORMULAIRE À LA THÈSE

Signature

L. Francescutti

Date

March 28, 1985

NL 91 (r. 84/03)

Canada

THE UNIVERSITY OF ALBERTA

PRODUCTION AND CHARACTERIZATION OF HEMOPOIETIC
ANTIBODY-FACILITATED CHIMERAS

by

(C) LOUIS HUGO FRANCESCUTTI

A THESIS

SUBMITTED TO THE FACULTY OF GRADUATE STUDIES AND RESEARCH
IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE
OF Doctor of Philosophy

IN

MEDICAL SCIENCES (IMMUNOLOGY)

EDMONTON, ALBERTA

SPRING 1985

THE UNIVERSITY OF ALBERTA

RELEASE FORM

NAME OF AUTHOR LOUIS HUGO FRANCESCUTTI
TITLE OF THESIS PRODUCTION AND CHARACTERIZATION OF
 HEMOPOIETIC ANTIBODY-FACILITATED
 CHIMERAS

DEGREE FOR WHICH THESIS WAS PRESENTED Doctor of Philosophy
YEAR THIS DEGREE GRANTED SPRING 1985

Permission is hereby granted to THE UNIVERSITY OF
ALBERTA LIBRARY to reproduce single copies of this
thesis and to lend or sell such copies for private,
scholarly or scientific research purposes only.

The author reserves other publication rights, and
neither the thesis nor extensive extracts from it may
be printed or otherwise reproduced without the author's
written permission.

(SIGNED) *L. H. Francescutti*.....

PERMANENT ADDRESS:

... 444 - 85th Avenue, ...
... Chomedey, Laval, ...
... Quebec, Canada. H7W 2Z5

DATED Thursday, March 14, 1985

THE UNIVERSITY OF ALBERTA
FACULTY OF GRADUATE STUDIES AND RESEARCH

The undersigned certify that they have read, and
recommend to the Faculty of Graduate Studies and Research,
for acceptance, a thesis entitled PRODUCTION AND
CHARACTERIZATION OF HEMOPOIETIC ANTIBODY-FACILITATED
CHIMERAS submitted by LOUIS HUGO FRANCESCUTTI in partial
fulfilment of the requirements for the degree of Doctor of
Philosophy in MEDICAL SCIENCES.

.....
Supervisor

.....
.....
.....

.....
External Examiner

Date..... 3/22/85

Dedication

I would like to dedicate this thesis to the memory of Stanley Amey, a close and dear friend, who provided me with inspiration and a sense of direction at just the right moment in my life.

Abstract

Complete hemopoietic takeover between semiallogeneic adults can be accomplished by the administration of antihost major histocompatibility complex (MHC) monoclonal antibody (mAb) and donor stem cells. The recipients of such treatment are termed antibody-facilitated (AF) chimeras, and they have been produced in BALB/cCR $\rightarrow$ (BALB/cCR x C3H/HeJ)F₁ and DBA/2J $\rightarrow$ (DBA/2J x C3H/HeJ)F₁ strain combinations. Donor stem cells can be derived from spleen, bone marrow, or T cell-depleted bone marrow. Engraftment by donor hemopoietic cells can be facilitated by mAbs directed toward Class I (anti-H-2K^k) or Class II (anti-H-2I-A^k) MHC antigens of the host. By monitoring isozymes of glucose phosphate isomerase, it can be shown that the establishment of donor hemopoiesis is stable, persisting for more than two years without graft-versus-host disease.

Examination of these AF chimeras reveals a correlation between peripheral blood chimerism and the stem cell constitution of both spleen and bone marrow. The peripheral blood chimerism also correlates with the level of chimerism in peritoneal exudate macrophages.

The development of these stable long-term AF chimeras across MHC barriers in the absence of irradiation or immunosuppressive agents may suggest a new approach to clinical bone marrow transplantation for certain conditions, such as aplasia and immunodeficiency syndromes.

Preface

Parts of the work described in this thesis have previously been published in *Transplantation Proceedings* and *Transplantation*.

Acknowledgements

The Department of Immunology and MRC Group on Immunoregulation at the University of Alberta possesses a unique environment for interaction at the scientific level. Students are given a generous opportunity to learn and more importantly to get involved.

With these thoughts in mind I would like to offer my sincerest appreciations to my supervisor Dr. Thomas Wegmann for the countless words of encouragement, the pats on the back, the "No's!", the "Yes's!", and for his friendship during these past years. To Dr. Erwin Diener, the Department Chairman, for the excellent frank discussions we've had. To Dr. Bhagarith Singh, for being himself and knowing exactly how to deal with graduate students. To the remaining members of my supervisory committee Drs. Michael Longenecker, Kwok-Choy Lee, Patrice Mannoni, Tim Mosmann and John Barrington-Leigh for their help and patience.

A very special note of thanks to my wife, Linda, for being the best friend a man could ever ask for.

Tanti ringraziamenti ai miei genitori, Angelo e Anna, per tutto cio che hanno fatto per avermi dato l'opportunita di andare a scuola. Io sono molto fortunato di essere vostro figlio, vi amero sempre.

Michael Voralia plowed through the original version of this thesis, to him and to Drs. Sharon LeClerc and David Sunahara thank you very much for your help with the

writings. No Soly, I haven't forgotten you! You are an excellent proofreader.

Thank you Dr. Sylvia Pollack, for serving as my external examiner, your suggestions were much appreciated.

To the remaining members of the Department, too numerous to mention, "Keep Smiling"!

Myron Wintonyk, a remarkable genius, deserves full credit for finding and solving the countless **Textform** problems encountered. Merci, mon ami!

Finally, to Phillip Gambel, what can I say, those were undoubtedly some of the best years of my life, thank you for your guidance, patience and craziness!

This work was supported throughout it's entirety by a studentship award from the Alberta Heritage Foundation for Medical Research to whom I am deeply indebted for their generosity.

In addition, Dr Wegmann's laboratory was funded by the Medical Research Council of Canada.

Chapter	Table of Contents	Page
I.	Introduction	1
II.	Clinical Bone Marrow Transplantation	2
	A. Severe Combined Immunodeficiency Disease	3
	B. Aplastic Anemia	4
	C. Acute Leukemia	7
	D. Other Hematogenous and Genetic Disorders	8
	E. Complications of Bone Marrow Transplantation	9
III.	Graft-versus-Host Disease	10
	A. Acute GVHD	11
	B. Chronic GVHD	15
	C. Graft-versus-Leukemia Effect	17
IV.	Hemopoiesis	19
	A. Fetal Hemopoiesis	19
	B. Hemopoietic Concepts	19
	C. Hemopoietic Microenvironment	21
	D. Hemopoietic Assays	23
V.	Experimental Bone Marrow Transplantation	26
	A. Radiation Chimera Model	26
	B. Drug-Induced Chimera Models	31
	Busulfan (BU) Treatment	32
	Cyclophosphamide (CY) Treatment	34
	5-Fluorouracil (FU) Treatment	34
	Hydroxyurea (HU) Treatment	35
	C. Parabiont Model	36
	D. Suppressor Cell Involvement in the Maintenance of Tolerance	37

E. Antibody-Facilitated Model: Introduction to The Research Project	39
VI. Materials and Methods	41
Mice	41
Monoclonal Antibodies	41
Radioiodination of Immunoglobulins	43
Ammonium Sulphate Precipitation	44
Preparation of Antibody-Facilitated (AF) Chimeras	45
Hematocrit determinations	47
Quantitation of Chimerism by the Gpi assay ..	47
Separation of Peripheral Red and White Blood Cells	48
Effects of mAbs on Pluripotential Stem Cells	51
Bone Marrow Fractionation	52
Long-Term Bone Marrow Cultures	54
Methyl Cellulose Cultures	56
2.1% Methyl Cellulose W/W ..	58
Spleen Conditioned Medium	58
Erythropoietin Production	59
Peritoneal Macrophages	60
VII. Results	61
A. Production of Antibody-Facilitated Chimeras	61
Production of anti-H-2K ^b Antibody-Facilitated Chimeras With Spleen Cells or Bone Marrow Cells or Both	61
Production of anti-H-2K ^b and anti-H-2I-A ^b Antibody-Facilitated Chimeras with anti-Thy 1.2 Treated Bone Marrow	63
Time Frame for Donor Inoculum	65

B. <i>In vivo</i> and <i>In vitro</i> Effects of mAbs on Hemopoietic Tissue	69
Effects on Hematocrits and Buffy Coats	69
Effects on the CFU-S Assay	72
C. Hemopoietic Analysis and Genotyping of Antibody-Facilitated Chimeras	75
Red and White Blood Cell Chimerism	75
Long-Term Bone Marrow Cultures	77
Genotyping of Peritoneal Macrophages	77
Residual Host Spleen, Lymph Node and Thymus Cell Populations	80
Correlation Between Proportions of Donor Cells in the Peripheral Blood and the Bone Marrow	80
Comparison of the Percentage Donor Cells in Peripheral Blood With the Percentage Donor Bone Marrow and Spleen-Derived Methyl Cellulose Colonies	83
Bone Marrow Fractionation	85
D. Allogeneic Antibody-Facilitated Chimeras Production	85
Using anti-H-2K ^b mAb	85
Using anti-H-2K ^b and anti-H-2I-A ^b mAbs	85
E. Health Status of Antibody-Facilitated Chimeras	89
Discussion	98
Future Directions	109
Bibliography	112
Vita	135

1. H-2 and <i>GpI</i> genotypes of mouse strains and the regions of the H-2 major histocompatibility complex recognized by the monoclonal antibodies used in these studies.	42
2. Production of Anti-H-2K ^k Antibody-Facilitated Chimeras with Spleen and/or Bone Marrow Cells. DBA/2J → D2C3F ₁	62
3. Production of Anti-H-2K ^k Antibody-Facilitated Chimeras with Spleen and/or Bone Marrow Cells. BALB → CC3F ₁	64
4. Production of Anti-H-2K ^k Antibody-Facilitated Chimeras with anti-Thy 1.2 Bone Marrow (α ⁺ BM) Cells.	66
5. Production of Anti-H-2I-A ^k Antibody-Facilitated Chimeras with anti-Thy 1.2 Bone Marrow (α ⁺ BM) Cells.	67
6. <i>In Vitro</i> Effects of Anti-H-2K ^k and Anti-H-2I-A ^k on CFU-S.	73
7. <i>In Vivo</i> Effects of Anti-H-2K ^k and Anti-H-2I-A ^k on CFU-S.	74
8. Ability of Long-Term Antibody-Facilitated Chimeras Sera to Inhibit CFU-S Appearance.	76
9. Peripheral Red and White Blood Cell Chimerism in Antibody-Facilitated and Radiation Chimeras.	78
10. Percent Donor Phenotype of Adherent and Nonadherent Cells in Long-Term Marrow Cultures and of Peritoneal Macrophages in Antibody-Facilitated Chimeras.	79
11. Donor Cell Contributions to Spleen, Lymph Nodes, and Thymus.	81
12. GPI Analysis of Peripheral Blood and Bone Marrow Fractions I, II, and III of AF Chimeras and Radiation Chimeras.	86
13. Attempts to Produce Fully Allogeneic Antibody-Facilitated Chimeras with Bone Marrow Cells and anti-H-2K ^k Monoclonal Antibody.	87

14. Attempts to Produce Completely Allogeneic Antibody-Facilitated Chimeras.	88
15. Attempts to Produce Fully Allogeneic AF Chimeras with Bone Marrow Cells and Anti-H-2K ^b and Anti-H-2I-A ^b mAbs.	90

Figure	List of Figures	Page
1.	Antibody-Facilitated Chimeras protocol.	46
2.	Electrophoretic migration patterns of glucose phosphate isomerase isozymes.	49
3.	Gpi standard curve.	50
4.	Bone marrow fractionation protocol.	53
5.	Gpi analysis of long-term bone marrow culture adherent and nonadherent cells.	55
6.	Technique for genotyping individual <i>in vitro</i> methyl cellulose bone marrow/spleen hemopoietic colonies.	57
7.	Variation in the time frame for the establishment of Antibody-Facilitated Chimeras.	68
8.	Effects of <i>in vivo</i> intravenous administration of anti-H-2I-A ^b (10-3.6) monoclonal antibody on hematocrits and buffy coats of various strains.	70
9.	Hematocrit determinations of AF Chimeras (BALB x C3H)F ₁	71
10.	Comparison of the percent of donor cells in peripheral blood and in the bone marrow of AF chimeras at various times post-transplantation.	82
11.	Comparison of the percent of donor cells in peripheral blood and bone marrow-derived or spleen-derived methyl cellulose colonies.	84

Plate	List of Photographic Plates	Page
1.	Photomicrograph of kidney from long-term AF chimera.	91
2.	Photomicrograph of liver from long-term AF chimera.	92
3.	Photomicrograph of lung from long-term AF chimera.	93
4.	Photomicrograph of section of kidney from a Group 2, anti-H-2K ^k AF Chimera.	95
5.	Photomicrograph of section of liver from a Group 2, anti-H-2K ^k AF Chimera.	96
6.	Photomicrograph of section of lung from a Group 2, anti-H-2K ^k AF Chimera.	97

List of Abbreviations

ABO	ABO human blood group
AF	antibody-facilitated
AML	acute myelogenous leukemia
α BM	anti-Thy-1.2 treated bone marrow
BALB	BALB/cCR
BFU-E	burst forming unit-erythroid
BM	bone marrow
BMT	bone marrow transplantation
BU	busulfan
C	centigrade
C3H	C3H/HeJ
CBA	CBA/CAJ
CC3F ₁	(BALB/cCR x C3H/HeJ)F ₁
CFU-E	colony forming unit-erythroid
CFU-EOS	colony forming unit-eosinophil
CFU-GM	colony forming unit-granulocyte-macrophage
CFU-MEG	colony forming unit-megakaryocyte-platelets
CFU-S	colony forming unit-spleen
CML	chronic myelogenous leukemia
CO ₂	carbon dioxide
cpm	counts per minute
CY	cyclophosphamide
CSA	colony-stimulating-activity

CSP	cyclosporin
CC3F ₁	(DBA/2J x C3H/HeJ)F ₁
DBA	DBA/2J
DLA	canine leukocyte antigens
DNA	deoxyribonucleic acid
EDTA	ethylene diamine tetraacetic acid
EPO	erythropoietin
F ₁	first progeny
FU	5-fluorouracil
GPC	guinea pig complement
Gpi	glucose phosphate isomerase enzyme
Gpi	glucose phosphate isomerase gene
GVH	graft- <i>versus</i> -host
GVHD	graft- <i>versus</i> -host disease
Hct	hematocrit
H&E	hematoxylin & eosin stain
Hh	hemopoietic histocompatibility gene
HLA	human leukocyte antigens
HU	hydroxyurea
iv	intravenous
Ig	immunoglobulin
¹²⁵ IUdR	¹²⁵ I-Iododeoxyuridine
L-PAM	L-phenylalanine mustard
M	Molar
mAb(s)	monoclonal antibody(ies)
mg	milligram(s)
MHC	major histocompatibility complex

min	minute(s)
ml	milliliter(s)
mm	millimeter(s)
MLC	mixed-lymphocyte-culture
ND	not determined
NK	natural-killer cells
P ₁	parental strain
PBS	phosphate buffered saline
R	irradiation
RNA	ribonucleic acid
rpm	revolutions per minute
RPMI	Roswell Park Memorial Institute
SD	standard deviation
SC	spleen cells
SCID	severe combined immunodeficiency disease
SCM	spleen conditioned medium
TBI	total body irradiation
TLI	total lymphoid irradiation
μg	microgram(s)
μl	microliters(s)
v/v	volume/volume
w/w	weight/weight

I. Introduction

Attempts to transplant hemopoietic tissue across major histocompatibility barriers, have met with a certain degree of success. Despite extensive efforts in both the experimental and the clinical models, however, a variety of problems still exist that must be overcome before bone marrow transplantation can achieve its full potential.

The objective of this chapter is to review the literature pertaining to the history of bone marrow transplantation, its use, and its present drawbacks. In addition, a review of hemopoiesis as it applies to the transplant model and a look at some of the past, present, and future animal models of bone marrow transplantation will be presented. Together, these topics will provide an overview of the current state of the art in cellular hemopoietic transplantation.

II. Clinical Bone Marrow Transplantation

Bone marrow transplantation (BMT) has, within the last 20 years, become the treatment of choice for a variety of hematologic diseases. Mathe *et al.*, in the late 1950's, described the use of unrelated donors in the treatment of individuals accidentally exposed to radiation. Although eventual rejection of the grafts occurred, the treatment allowed for endogenous repopulation by the host hemopoietic tissue to occur (Mathe, 1959). Reports of controlled studies relating to the clinical application of transplantation, using thymic, fetal liver, and bone marrow cells, began appearing in the 1950's and 1960's (Uphoff *et al.*, 1958; Pegg 1960; Hong, 1968a; Gatti *et al.*, 1968; Cleveland *et al.*, 1968; August *et al.*, 1968). Since those initial days, a considerable degree of success has been seen in the treatment of severe aplastic anemias (Gluckman *et al.*, 1981), some leukemias (Thomas *et al.*, 1977a, 1977b, 1979), certain immunodeficiency diseases (Pahwa *et al.*, 1978), and even in genetic disorders of hemopoiesis (Thomas *et al.*, 1982). Despite these recent advances, several drawbacks still exist, including graft-versus-host disease (GVHD) (Storb *et al.*, 1983a; Gale, 1982), opportunistic infections (Meyers, 1982a, 1982b, 1984; Sullivan *et al.*, 1984; Winston *et al.*, 1984; and Buckner *et al.*, 1984), and the lack of complete immunological reconstitution (Witherspoon *et al.*, 1984a, 1984b). Several of these problems are a direct result of the irradiation and immunosuppressive regimens used in

the preparation of the patient prior to engraftment. It will soon become apparent, that to date, no acceptable means of host preparation prior to transplantation has been achieved. The effects of the irradiation and the cytotoxic agents used, are still far too nonspecific in their mode of action. Our results suggest a new approach to circumventing these problems. Let us now consider certain conditions in which some degree of success has been achieved.

A. Severe Combined Immunodeficiency Disease

A little over a decade and a half ago, Good and his colleagues reported the successful correction of a X-linked form of severe combined immunodeficiency disease (SCID) (Hong *et al.*, 1968a; Gatti *et al.*, 1968). Although the marrow engrafted and subsequently corrected the state of immunodeficiency, an immunologically based aplastic anemia ensued as a result of a mismatch at the HLA-A locus (Gatti *et al.*, 1971a). This was corrected by a second marrow transplantation using an HLA-matched sibling as a donor (Gatti *et al.*, 1971b).

In patients with SCID, an immunosuppressive regime is not required since these patients are already immunodeficient. Therefore, the success rate is very high if HLA-identical siblings are used as donors (Meuwissen *et al.*, 1969). A severe GVH reaction occurs if donor and recipient are not HLA-matched (Biggar, 1973; Park, 1974). Recently, Reisner *et al.* have attempted to remove or inactivate T

cells in the donor marrow responsible for the GVH reaction by means of fractionation techniques, and their results look promising (Reisner et al., 1983).

B. Aplastic Anemia

A somewhat more complicated situation exists in the case of aplastic anemia. Aplastic anemia is an example of a major hypoproliferative disorder of the bone marrow. It should be noted that the marrow is not truly 'aplastic' but hypoplastic. Areas of normocellular as well as hypercellular marrow can be found in certain cases, although 2/3 of them are apparently idiopathic (Beck, 1982). Some causative agents have been associated with the onset of aplastic anemia. Most noticeable among these are ionizing radiation, benzene and its derivatives, various cytostatic agents, some classes of drugs and viral infections like hepatitis-B. The onset of symptoms is usually insidious. The individual presents with anemia, thrombocytopenia, and an increased incidence of infection, as a result of neutropenia. Therapeutic modalities include supportive transfusions, steroids, stimulation of the marrow with androgens, and possible splenectomy. It has been shown that transplantation can lead to a significantly better survival rate than supportive measures alone (Camitta, 1979). Although the marrow in these patients is partially hypoplastic and, in a sense, an ideal site for donor marrow to engraft, major problems must be overcome. One must find a HLA identical

donor as defined by antigenic HLA identity and non-reactive MLC and even in such case the rejection of the donor marrow cells can still occur by the immunologically competent host. Currently the preparative immunosuppressive regime consists of the administration of cyclophosphamide (CY), 50 mg/kg for 4 days. Some centres also include 750 rad total lymphoid irradiation (TLI) in the regime (Storb and Thomas, 1983a; Ramsay *et al.*, 1980; Kersey *et al.*, 1980).

Graft rejection and secondary immunodeficiency can occur, and can be directly related to the regime of immunosuppression used in the transplantation. On the one hand it is possible to reduce the rate of graft rejection by increasing the severity of the immunosuppressive regime, while on the other hand this will probably increase the risk of iatrogenic complications such as infections.

Several factors have been identified which enhance graft rejection. For instance, multiple-transfusion and hence sensitization of the patients prior to grafting; a low number of transplanted marrow cells ($<3 \times 10^6/\text{kg}$); and marrow grafts from male donors (Storb, 1977, Storb *et al.*, 1983b). The Seattle Marrow Transplant Team has performed 39 transplants in patients who had not previously been transfused. Thus far, 83 % of their patients have survived between 2 and 9.5 years post grafting (Storb *et al.*, 1980).

In patients who had previously received multiple-transfusions, the transplant protocol included the addition of donor buffy coat cells. This modification

improved the 2 - 6 year survival rate from 45 % in patients not receiving buffy coat treatment to 75 % survival in those receiving these additional cells. It was postulated that these findings were analagous to the enhancement of allogeneic marrow engraftment seen experimentally in mice and dogs. One must bear in mind that this modification also increases the incidence of chronic GVHD, while not affecting the mortality rate (Storb *et al.*, 1982a).

Several recent studies indicate that the use of Cyclosporin-A (CSA) can reverse transfusion-related sensitization and lower the likelihood of the marrow graft being rejected (Storb *et al.*, 1982b; Hows *et al.*, 1982). Attempts to prevent sensitization by ABO-and HLA-typing the patient and trying to find suitably matched donors has been instituted in some centres. Ideally, patients identified as being likely candidates for BMT should be transplanted as soon as possible in light of the success of the Seattle Marrow Transplant Team and other centres around the world that use this principle (Storb, 1980).

Finally, Ildstad and Sachs (1984) have used an animal model to show that reconstitution of irradiated hosts with T cell depleted bone marrow, containing both syngeneic (host) as well as allogeneic (donor) cells, leads to long-term survival of the reconstituted animals as well as prolongation of donor skin grafts. Interestingly, these recipients are able to mount normal immune responses to third party antigens and show no signs of GVHD.

C. Acute Leukemia

Bone marrow transplantation in leukemic patients is somewhat similar to the situation in aplastic anemia, although graft rejection is rarer. This is no doubt due to the use of high doses of total body irradiation (TBI) to destroy the leukemic cells. It has been noted that the occurrence of GVHD also exhibits a peculiar graft-versus-leukemia effect, to be discussed later.

Hobbs (1983) and Bortin (Bortin *et al.*, 1982) reported that BMT is the treatment of choice for acute myelogenous leukemia (AML) as compared to chemotherapy alone, providing the patient is under 40 years of age, is engrafted with an adequate number of cells ($>2.2 \times 10^8$ nucleated cells/kg body weight) from a compatible sibling donor while in first complete remission, and before he has been multiple-transfused (<22 times). In children, a long-term survival rate of 70 % has been the experience of Good (Good *et al.*, 1983). In acute nonlymphocytic leukemia in first remission, Thomas reports survival rates in unmaintained first remission of 55 %; similar findings are also reported in other centres, where rates of apparent cure range from 35 % to 65 %, depending on the age group (Thomas *et al.*, 1982; Thomas *et al.*, 1984; Forman *et al.*, 1983; Blume *et al.*, 1980). Patients presenting with chronic granulocytic leukemia in blast crisis and undergoing marrow grafting show survival rates of approximately 30 % (Thomas *et al.*, 1984).

D. Other Hematogenous and Genetic Disorders

Recent articles summarize the many other diseases in which BMT can be used as an effective therapeutic modality. These include Wiskott-Aldrich syndrome, Blackfan-Diamond syndrome, Fanconi anemia, severe neutrophil dysfunction, chronic granulomatous disease of childhood, severe (Kostman-type) agranulocytosis, infantile osteopetrosis, Burkitt's lymphoma, Hodgkin's disease, myelofibrosis, preleukemia, and multiple myeloma (Good *et al.*, 1983; Thomas *et al.*, 1984; Appelbaum *et al.*, 1984; Iriondo *et al.*, 1984). However, Thomas notes the need for more organized studies before the full potential of BMT can be realized in these patients.

Recently, bone marrow transplantation has been used with some success in treating the twitcher mouse, the animal model of galactosylceramidase deficiency (Krabbe's disease). Prolonged survival and gradual repair of demyelination in peripheral nerves is seen, although improvements in the CNS were not noted. The latter observation is most likely related to the involvement of the blood-brain barrier, which may be acting as an impervious barrier (Yeager *et al.*, 1984).

An exciting recent development has been the advent of gene transfection and its potential application to defective stem cell therapy. This subject will be considered later in the Conclusion.

Despite the advances in BMT for the treatment of the various disorders just reviewed, several problems still exist and will be considered next.

E. Complications of Bone Marrow Transplantation

Deeg *et al.*, (1984a) have recently reviewed the delayed complications of BMT, such as problems associated with engraftment, like acute or chronic GVHD, immunodeficiencies and associated infections. They also discuss the inherent complications of chemotherapy and irradiation when these are used as immunosuppressive preparatory regimes, for example pulmonary fibrosis and occlusive disease of the liver. One also finds neurologic complications, endocrine dysfunction and infertility, the appearance of cataracts, and the development of secondary malignancies. Reoccurrence of the disease being treated is also a frequent complication. The overall theme of this review is one of caution. BMT has significantly improved the chances of surviving a variety of disorders but the preparative regime is still far too toxic for more widespread use. As one of the principal complications is GVHD, I now consider it in more detail.

III. Graft-versus-Host Disease

The occurrence of either acute or chronic graft-versus-host disease (GVHD) post-transplantation has been attributed to donor T lymphocytes in the marrow graft. These T cells recognize host histocompatibility antigens as being foreign and subsequently mount an immune based assault (Sprent and Miller, 1972; van Bekkum, 1980; Storb, 1984; Tsoi *et al.*, 1982, 1983; van Bekkum *et al.*, 1979; Pals *et al.*, 1984a, 1984b; Micklen and Loutit, 1966; Elkins, 1971; von Boehmer *et al.*, 1975a). GVHD is seen primarily in situations where the host is unable to reject the grafted donor cells. These situations exist in immunologically immature individuals, in immunodeficient patients, and in those who have undergone an immunosuppressive treatment (for example TBI or cytotoxic drugs).

GVHD has a preference for certain target organs: in both animals and humans, the skin, gastrointestinal tract, and liver seem to be particularly susceptible. In addition, some studies have indicated that in dogs, the involvement of the bronchial glands, the salivary glands, and the prostate is evident (Thomas *et al.*, 1975; van Bekkum and de Vries, 1967; Glucksberg *et al.*, 1974; Grebe and Streilein, 1976; van Bekkum *et al.*, 1979).

A. Acute GVHD

The cause of acute GVHD has been assumed to be the presence of immunocompetent T cells in the marrow graft (Grebe and Streilein, 1976; Sprent and Miller, 1972). This has been borne out by studies in which immunosuppressive agents, such as xenogeneic anti-lymphocyte serum, anti-theta monoclonal antibodies, methotrexate, cyclophosphamide, and cyclosporin, have been shown to prevent or reduce the severity of the GVHD (Rödt, 1974, 1981; Korngold, 1983; Prentice, 1982; Filipovich, 1982; Storb, 1980). The presence of these cells varies between species, being few in number in mouse bone marrow, intermediate in the dog bone marrow, and abundant in monkey and human bone marrow. The degree of MHC mismatching between donor and recipient has been shown to be directly related to the degree of severity of the ensuing acute GVHD (Storb *et al.* 1973; 1976). Pritchard and others have also suggested that the host's genetic background, for example, non-MHC genes and/or antigens, may play an important role in modifying the severity of a graft-versus-host (GVH) reaction (Cantrell and Hildemann, 1972; Pritchard and Halle-Pannenko, 1981; Halle-Pannenko *et al.*, 1980). Indeed, Pritchard and her colleagues now have direct evidence for the involvement of the MLS locus in death from GVHD in mice (Pritchard *et al.*, personal communication 1984). In the dog model, Storb has shown that the probability of survival of marrow grafts between DLA-identical littermates is far superior to

DLA-haploidentical matching. Similar findings have been reported in man, where HLA-identical siblings show a higher rate of successful engraftment when compared to the haploidentical situation (Storb *et al.*, 1983b).

The clinical appearance of acute GVHD in man manifests itself as an initial involvement of the skin, with subsequent involvement of the liver and intestines. Acute GVHD has been classified into four different stages, depending on the severity of involvement of the target organ systems. In addition, Thomas *et al.*, (1975) has proposed a clinical grading scale from 0 to IV, which takes the staging classification a step further (Glucksberg *et al.*, 1974). The histopathology associated with acute GVHD has been extensively reviewed (Thomas *et al.*, 1975; van Bekkum and de Vries, 1967; Sale *et al.*, 1977, 1979; Simonsen, 1962; Hansen *et al.*, 1981; Beschorner *et al.*, 1982; Gleichmann *et al.*, 1976, 1982; Rolnink *et al.*, 1982, 1983a, 1983b; Rappard-van der Veen *et al.*, 1983). Skin changes can include basal vacuolar degeneration or necrosis; localized dermal-epidermal separation; infiltration and damage by eosinophils and other types of cells. Lymphocytic infiltration may occur in a variety of areas, such as joints or salivary glands. A full blown Sjögrens syndrome may appear. A number of other disease-like syndromes can occur, resembling such things as scleroderma, periarteritis, and systemic lupus erythematosus with immune complex glomerulonephritis. Lymphoproliferative syndromes may occur

and can encompass the spectrum from benign lymphoid hyperplasia to malignant lymphoma. An alternative may be the appearance of a lymphoid hypoplastic syndrome with thymic aplasia, pancytopenia, and disappearance of plasma cells from the gut.

One can readily appreciate that while all these pathologic events are occurring, the likelihood of the recipient succumbing to opportunistic infection is very high. In a clinical review, Thomas found that in the first 3 to 4 months post-transplantation, recipients were prone to a variety of bacterial, viral, and fungal organisms (Thomas et al., 1975). Management of the bacterial and fungal infections involved the use of appropriate antibiotics, including amphotericin B, and when deemed necessary, granulocytic transfusions were administered. Pneumonia due to *pneumocystis carinii*, a previously serious post-transplantation complication, has recently been effectively prevented by the prophylactic use of trimethoprim-sulfamethoxazole. Interstitial pneumonias, appearing one to three months post-transplantation, remains a major problem.

Meyers and Storb separately reported that the use of cyclophosphamide as compared to TBI reduces the incidence of interstitial pneumonia from 40 - 50 % to 16 % (Meyers and Thomas, 1982a; Storb et al., 1982b). Approximately 60 % of the pneumonias are associated with cytomegalovirus involvement; of these, 50 % are fatal. However, O'Reilley

and Meyers have recently reported that the use of cytomegalovirus hyperimmune globulin can influence the outcome of these highly fatal viral pneumonias (O'Reilley *et al.*, 1983; Meyers *et al.*, 1983). The Seattle Marrow Transplant Team has found that decontamination of the normal flora of the recipient in conjunction with the use of laminar air flow rooms has decreased the incidence of GVHD and increased the survival rate (Storb and Thomas, 1983a; Deeg, 1983; Thomas *et al.* 1975; Solberg, 1971).

The occurrence of GVHD can be predicted neither on the basis of sex-matching the donor and recipient nor on the number of marrow cells or buffy coat cells infused. Vallera *et al.*, (1983) have attempted to remove T cells from the donor inoculum using ricin linked to a variety of mAbs specific for differentiation antigens on the surface of the T cells lymphocytes. They found that by using mixtures of these immunotoxins, they could significantly kill T lymphocytes. Current therapy for established acute GVHD consists of the use of methylprednisone, (Kanojia *et al.*, 1984), anti-thymocyte globulin, and, recently, murine monoclonal anti-T-antibodies (Remlinger *et al.*, 1984). Using a new monoclonal rat anti-human lymphocyte antibody *in vitro*, Waldmann *et al.*, (1984) were able to prevent the development of GVHD in 11 high-risk patients who had received treated marrow from HLA-matched siblings. T cell levels post-depletion, as measured by both erythrocyte-rosette formation and immunofluoresence with a

monoclonal anti-T cell antibody, were less than 0.5%. Martin *et al.*, (1984) were not as successful with their protocol, which involved using murine monoclonal anti-T cell antibodies without complement; graft-versus-host disease remained a problem in their studies.

The immunological recovery of patients in which cyclosporin (CSP), in contrast to methotrexate, is used for the prevention of GVHD, has been compared (Witherspoon *et al.*, 1984a). Evaluation of various immunological parameters, such as Ig levels and cell mediated immunity, suggests that recovery is comparable between the two treatments. Although CSP is useful in reducing the incidence and severity of GVHD, it has deleterious side-effects such as hypertrichosis, gum hypertrophy, a rare but serious "capillary leak" syndrome, and serious neurological illnesses, such as motor spinal cord syndrome, a cerebellar-like syndrome, and mental confusion (Atkinson *et al.*, 1984; Witherspoon *et al.*, 1984a; Morris, 1984; Deeg *et al.*, 1984b; Harper *et al.*, 1984). It should be noted that the neurological disorders were successfully controlled by either reducing the dosage or eliminating the CSP from therapy. Let us now look at another form of GVHD.

B. Chronic GVHD

Even if HLA-identical marrow is used in BMT, chronic GVHD still occurs in some cases for unknown reasons, presumably related to minor histocompatibility mismatching

(Storb, 1983). Of 130 patients transplanted with HLA identical grafts for aplastic anemia, 45 % developed chronic GVHD between 3 to 15 months post-transplantation. Reports from several centers indicate that the main clinical findings include epidermal disease, obliterative bronchiolitis, severe buccal mucositis, keratoconjunctivitis, gastrointestinal involvement, and liver dysfunction, among others (Glucksberg, 1974; Saurat *et al.*, 1975; Gleichman *et al.*, 1984; Graze and Gale 1979; Sullivan *et al.*, 1981; Weiden *et al.*, 1980; Ralph *et al.*, 1984; Shulman *et al.*, 1980). The likelihood of developing chronic GVHD is related to whether the patient previously manifested acute GVHD. An increase in the severity of acute GVHD is directly correlated with the occurrence of chronic GVHD (Storb, 1983c). The incidence of chronic GVHD is higher with increasing age. It has been suggested that this is related to thymic epithelial function.

Chronic GVHD can be controlled in a third of all cases by the administration of prednisone, either alone or in combination with procarbazine, cyclophosphamide, or azathioprine (Storb, 1984). Efforts to prevent the development of chronic GVHD by using steroids have yielded conflicting results (Forman *et al.*, 1982; Ringden *et al.*, 1982).

Considering the morbid complications associated with GVHD, it soon becomes obvious that protocols must be developed which will prevent or reduce the likelihood of the

occurrence of GVHD.

In contradiction to what has just been said, there is some speculation that a certain degree of GVHD may be beneficial in the promotion of hemopoietic activity post-transplantation. Equally interesting is the finding that GVHD may, in some unique way, also effect an anti-leukemic response , our next topic of discussion.

C. Graft-versus-Leukemia Effect

Barnes and Louitt (1956) and Bortin (1979, 1981) reported the observation that marrow cells transplanted into irradiated mice could destroy any radioresistent leukemic cells. A similar situation has been noticed in humans, where Weiden (Weiden *et al.*, 1979; 1980) has found that both acute and chronic GVHD exert an antileukemic effect. Analysis of 163 recipients with acute nonlymphoblastic leukemia or acute lymphoblastic leukemia transplanted while in remission or relapse reveals that the likelihood of achieving and/or maintaining a remission is greatest in patients who had either acute or chronic GVHD and lowest in those without any evidence of GVHD. The survival rate also increases, with those having undergone chronic GVHD showing an 80 % survival rate, 50-55 % for those with acute or acute and chronic GVHD and 25-30 % for those patients without GVHD. These results have stimulated a great deal of interest in the graft-versus-leukemic effect. Studies aimed at modifying the effects of GVHD to maximize its antileukemic effect are in

progress.

We will now consider the role of hemopoiesis as it relates to the transplant model.

IV. Hemopoiesis

Bone marrow transplantation *per se* is a relatively simple and straightforward procedure. The inherent problems associated with it are post-transplantation GVHD, possible incomplete reconstitution of the immune system, development of subsequent opportunistic infection, and the failure of the marrow to engraft. The requirements for hemopoiesis play a key role in engraftment.

A. Fetal Hemopoiesis

In the mouse it is known that blood islands arising from mesenchymal cells during the mesoblastic period of hemopoiesis are the site of erythropoiesis in the yolk sac (Metcalf and Moore, 1971). These cells, incidentally, have been successfully transplanted into lethally irradiated animal recipients. In the human, the seeding of the liver occurs at six weeks and that organ then becomes the chief site of hemopoiesis in the embryo. As time progresses, the hemopoietic potential shifts to the spleen and finally to the bone marrow (Zucker-Franklin, 1981).

B. Hemopoietic Concepts

Circulating and fixed blood cells such as platelets, fixed and free macrophages, erythrocytes, granulocytes, and lymphocytes are constantly turning over, hence the requirement for a constant renewal and replenishment of their numbers. Renewal is achieved by means of a pluripotent

stem cell compartment which responds to the demands for replenishment of the various cell lineages. This can best be simplified into a three-tiered structure where the ultimate stem cell, as yet not identified, is a totipotent cell capable of giving rise to a variety of pluripotent cells as well as having the unique potential of self-renewal. The second level represents the progenitor cell compartment: it is here that we start to see differentiation into the various lineages. A common lymphoid progenitor is believed to give rise to either B or T cell precursors. A pluripotent myeloid stem cell can differentiate into BFU-E, burst-forming unit, erythroid; CFU-E, colony-forming unit, erythroid; CFU-EOS, colony-forming unit, eosinophil; CFU-GM, colony-forming unit, granulocyte-macrophage; or CFU-MEG, colony-forming unit, megakaryocyte-platelets. Finally, the last tier represents the mature or so-called effector cells such as polymorphonuclear cells, monocytes-macrophages, erythrocytes, platelets, eosinophils, basophils, various T lymphocytes subsets and B-lymphocytes.

Two important concepts have been established with regards to the first two tiers. Microenvironmental factors play a key role in determining the commitment of multipotential stem cells to a particular differential pathway, and the proliferation of the progenitor cells is greatly influenced by specific humoral factors, for instance the effect of erythropoietin on erythropoiesis, or CSF-GM on granulopoiesis.

C. Hemopoietic Microenvironment

Undoubtedly, one of the most important and interesting aspects of hemopoietic transplantation is the concept of the "microenvironment", the proposed site of stem cell induction. Unfortunately, it is very difficult to study the microenvironment *in vivo* and until recently, no assay existed which would allow one to better understand exactly what goes on at this unique site of cellular interaction. Keller (1979) in an elegant set of *in vivo* experiments showed that both granulocytic and erythrocytic colonies could develop on the chick embryo chorioallantoic membrane. He showed, quite conclusively, that a stromal cell population of the chick embryo spleen, represented the hemopoietic microenvironment. In a set of *in vitro* experiments, Dexter and Moore (1977a) demonstrated the direct involvement of this so-called microenvironment in the maintenance of hemopoiesis. They established, in long-term bone marrow cultures, an adherent environmental monolayer consisting of phagocytic mononuclear cells, flattened epitheloid-like cells, endothelial cells, reticular cells, and giant fat-containing cells. (Incidentally, Spooncer *et al.* (1981) showed that the presence of certain glycosaminoglycans such as heparin sulphate, chondroitin sulfate, and hyaluronic acid were important factors that contributed to the growth of these cultures). Using the anemic W/Wv and Sl/Sld mouse strains, which have, respectively, either defective stem cells (and a competent

environment) or a defective environment (and competent stem cells), Dexter showed that adherent layers derived from the W/Wv strain bone marrow could support stem cell activity of the Sl/Sld strain, while the Sl/Sld adherent layer failed to develop. This strongly suggested the importance of cellular interaction between the stem cells and the microenvironmental compartment, in this case represented by the monolayer of adherent cells.

Moore and his colleagues then extended this concept to see if adherent layers of a particular genetic strain could indeed support the growth of allogeneic hemopoietic cells. Using semiallogeneic or allogeneic bone marrow combinations, CBA/Cum (H-2k) $\rightarrow$ C57Bl/6 (H-2b) or in the opposite direction; CBA/Cum $\rightarrow$ (CBA/Cum x C57Bl/6)F₁; C57Bl/6 $\rightarrow$ (CBA/Cum x C57Bl/6)F₁; CBA/Cum $\rightarrow$ CBA/Cum and C57Bl/6 $\rightarrow$ C57Bl/6, they reported that bone-marrow derived adherent cells could stimulate the growth of both syngeneic and allogeneic hemopoietic cells. In their summary, they clearly indicate that the cells responsible *in vivo* for transplantation resistance and GVHD may simply not exist in the *in vitro* culture conditions and that these results should not be overinterpreted. The question as to whether the marrow stroma is a transplantable element is addressed in the Discussion.

Schofield (1978) talked of a hemopoietic concept known as "niches", which represented a clustering of various microenvironmental support cells in association with stem

cells. This proposed model of a close interaction network would allow for cell-cell communication to occur and allow short-range factors to be effective. This concept has been supported by studies which have shown that hemopoietic tissue is not a randomly distributed arrangement of a mixture of various cells but in fact the opposite (Trentin 1970, 1978). Examination of the morphological arrangements of cells within the mouse femur have shown that an orderly pattern does indeed exist, quite similar to the "niche" concept (Weinbeck, 1938; Lord and Hendry, 1972; Frassoni *et al.*, 1982; Hendry and Lord, 1982; Xu and Hendry, 1981).

The implication of thymus-derived cells in the promotion and maintenance of hemopoietic activity has been proposed by several groups (Lord and Schofield, 1973; Goodman and Shimpock, 1968, 1972; Dexter *et al.*, 1973; Vallera *et al.*, 1982). These findings are of particular interest given the extensive efforts being made to remove T cells from the donor inoculum, in an attempt to reduce the incidence of GVHD. This interesting observation suggests that T cells may not be required, despite reports of their involvement in hemopoiesis.

D. Hemopoietic Assays

Since the initial CFU-S assay described by Till and McCulloch (1961), a variety of equally useful *in vitro* and *in vivo* culture systems have proven to be extremely beneficial in determining the origin of various cell

lineages post-transplantation. As mentioned previously, Dexter's introduction of *in vitro* long-term bone marrow cultures allowed for the investigation of not only the stem cell (nonadherent) population but more importantly the microenvironmental (adherent) cell population as well (Dexter *et al.*, 1973, 1977b).

This culture system allows for both the establishment, *in vitro*, of an environment which promotes self-renewal of the stem cell population, as well as commitment of progenitor cells to occur. *In vitro* assays which allowed the committed cells to be identified, provided the much needed link to hemopoietic investigation of various cell lineages containing the major cell types (Wolf and Trentin, 1968; Fauser and Messner, 1979; Pluznik and Sachs, 1965; Bradley and Metcalf, 1966; Metcalf, 1977; Metcalf and Johnson, 1978; Metcalf *et al.*, 1979; Dorshkind and Phillips, 1983). By using these assay systems, it is also now possible to investigate the origin of related marrow derived cell lineages. Examples include Langerhans' cells in the epidermis, osteocytes in the bone, and a variety of tissue macrophages.

The rapid recent development in these hemopoietic assays has been directly associated with the discovery of various humoral factors that promote the *in vitro* growth of hemopoietic cells. The most extensively studied factor, colony-stimulating-activity (CSA), is made by conditioning medium with peripheral blood leucocytes in the presence of

phytohemagglutinin (Fausner and Messner, 1979).

These assay systems have been used extensively in this thesis to show that once engraftment has been established in our model, it remains a permanent phenomena.

Our earlier discussion of BMT concerned itself primarily with various aspects of the clinical model. Let us now review the production of animal bone marrow chimeras by means of irradiation, cytotoxic drugs, a combination of both, and by a novel approach that utilizes anti-host monoclonal antibodies (mAbs).

V. Experimental Bone Marrow Transplantation

A. Radiation Chimera Model

Earlier studies on radiation-induced bone marrow transplantation were extended by von Boehmer *et al.*, (1975a, 1975b), who realized the potential of this *in vivo* model for studying T-B cell interaction. They successfully reduced the detrimental effect of the graft-versus-host reaction by eliminating mature peripheral blood T cells, utilizing anti-Thy 1 antibody and complement. This does not prevent normal stem cell development in the irradiated recipient. The basic model employed was to repopulate 800-900 rad irradiated ($P_1 \times P_2$)F₁ hybrids with either P₁ and/or P₂ donor cells. Subsequent development of either P₁ or P₂ donor stem cells in the chimeric environment rendered them mutually tolerant of each other.

Several groups then reported that chimeric T cells of P₁ origin which had differentiated in the ($P_1 \times P_2$)F₁ environment could cooperate equally well with B cells originating from either P₁ or P₂: the same applied to the P₂ cells differentiating in ($P_1 \times P_2$)F₁ environment (Waldmann *et al.*, 1978; Kappler and Marrack, 1978; Sprent and von Boehmer, 1979; Singer *et al.*, 1979; Zinkernagel *et al.*, 1978; Santos *et al.*, 1979; Bevan, 1977; Longo and Davis, 1983). Restriction specificity therefore, appears to be learned during the antigen-independent differentiation of T cells in the F₁ environment (Tada, 1984).

Kappler and Marrack (1978) and Longo *et al.*, (1981) used the radiation chimera model to study whether T cell precursors of non-responder type could respond to antigen presented by antigen-presenting cells of the responder type. They found that when non-responder T cells, which had matured in an (responder x nonresponder)F₁ environment and which were tolerant of responder MHC antigens, were then primed in the presence of (responder x nonresponder)F₁ antigen-presenting cells, they responded. Paul (1984) summarizes these findings by stating that: ".... unresponsiveness to antigen is not an innate property of T cells from a non-responder animal; in the proper setting, such T cells can respond - but what they respond to is the pair of antigen and responder Class II molecules."

In terms of the hemopoietic makeup of radiation chimeras, Cudkowicz and Stimpfling (1964), and Lotzová and Cudkowicz (1973) found resistance and deficient growth of bone marrow grafts. This resistance has been referred to as "hybrid-resistance", a topic we will now consider. Many reports have appeared with respect to the ability of various strain combinations to successfully engraft following irradiation. Daley and Nakamura (1984) showed that the natural resistance of H-2b/d and H-2b/k F₁ hybrid mice against parental H-2b bone marrow grafts was mediated by effectors restricted by the *H-2Db/Hh-1b* gene(s). This confirmed that the natural-killer (NK)-like effector cells, thought to mediate natural resistance in the P → F₁

irradiation model, are restricted, and this contrasts with reports of unrestricted NK cell activity against a wide range of tumors and normal cells. This restriction was previously postulated as being under the control of a set of unique noncodominant genes denoted as *Hh* (hemopoietic histocompatibility) (Snell, 1976).

Lotzová and her colleagues have shown that natural-killer (NK) cells are actively involved in the mechanism of allogeneic bone marrow graft rejection (Lotzová and Savary, 1977; Lotzová and Gutterman, 1979; Lotzová, 1980; Lotzová *et al.*, 1983). They showed that the *in vivo* treatment with an antiserum specific against the NK-cell surface antigen NK 1.1, as previously described by Pollack *et al.*, successfully prevented the rejection of allogeneic bone marrow transplants (Pollack *et al.*, 1979).

Using a cloned cell line with NK activity, Warner and Dennert (1982) were able to show that this line, when injected into syngeneic NK-deficient mice had an effect *in vivo*. The ability of the NK-deficient mice to reject allogeneic bone marrow was shown to be specific, in that identity at the H-2 locus precluded rejection while H-2 disparity was associated with rejection. Using congenics and recombinants they were able to narrow the target antigens to the H-2D region primarily. Further implications of the role that NK cells play in hemopoiesis and allograft marrow transplantation comes from studies by Hansson *et al.*, 1982. They reported that human NK cells have the ability to

inhibit *in vitro* granulopoiesis of autologous and allogeneic bone marrow cells. This strongly suggests that NK cells may possibly play a role *in vivo* as a regulatory of certain aspects of hemopoiesis.

Using various congenics, recombinants, and F₁ hybrids, Drizlikh *et al.*, (1984) report that both Class I (K and D) and Class II (I-A and I-E) MHC genes, rather than hypothetical *Hh* genes, are actually responsible for the phenomenon of hemopoietic resistance. They examined the ability of irradiated (H-2b x H-2k)F₁ and (H-2b x H-2d)F₁ recipients to prevent the growth of H-2b parental BM cells, without impeding the engraftment of non-H-2b parents. The authors explain that the *Hh* restriction phenomenon is only seen in certain strain combinations because "... there exist parental determinants that are not formed in some F₁ hybrids due to preferential association of either Ia alpha chains with allogeneic beta chains or of Class I antigens with allogeneic or hybrid Class II restriction elements." Their results cannot be accepted as conclusive, since their use of congenics and recombinants does not necessarily prove that *Hh* genes do not exist.

Carlson and Wegmann (1977) found that by monitoring the elimination and metastatic potential of ¹²⁵I-iododeoxyuridine prelabeled H-2^d leukemia cells, they could study *in vivo* models of hybrid and allogeneic resistance. Using an ingenious technique of whole-body gamma counting along with colonization of the spleen, they were

able to describe that although all nonirradiated mice showed early recognition and elimination of cells which were not H-2 identical with self, as one would expect; irradiation had varying effects on different strains of mice in their ability to reject the labelled leukemic cells. They concluded that although dissimilarities at the H-2 locus provided the targets for recognition, non-H-2 genes played a role in the susceptibility of the rejection process to irradiation.

When the role of irradiation was previously considered as a means of preparing patients prior to BMT, its drawbacks were not discussed quite adequately. Van Bekkum (1980) showed quite clearly that GVHD is enhanced by TBI, but this has not been confirmed by others. In addition Deeg *et al.*, (1983) have found that canine radiation chimeras prepared with TBI have an estimated relative risk of developing a malignancy that was 5-fold higher than in control dogs.

In light of these difficulties, new methods were introduced which attempted to address these problems. Slavin and Strober, in animal models, selectively irradiated areas that were rich in lymphoid tissue while shielding the rest of the body (Slavin *et al.*, 1979a; Slavin and Strober, 1979b). They delivered the radiation by means of multiple small fractionated doses, for example, 200 rad x 17. Using this approach, they found that they were capable of transplanting across allogeneic barriers without any sign of GVHD. As well, they showed that immunological tolerance was

induced and that both nonspecific and specific suppressor T cells appeared.

Slavin and Seidel, (1982) examined the hemopoietic status of these TLI bone marrow chimeras and found the following. TLI did not cause irreversible damage to the marrow. In fact, the procedure allowed a larger total cumulative radiation dosage to be administered. This advantage of TLI has successfully been used in the clinical situation, in radiotherapy prior to bone marrow and organ transplantation, and also in attempts to treat various autoimmune disorders (Strober *et al.*, 1979; Slavin *et al.*, 1979b).

It has been reported that no neoplasms were detected in an ongoing study of drug-induced chimeras prepared with cyclophosphamide or dimethyl busulfan, suggesting that the drug regime may be a better preparatory protocol than irradiation (Deeg *et al.*, 1983).

Several classes of drugs may be used in the preparation of a recipient prior to BMT. The following are representative agents.

B. Drug-Induced Chimera Models

Alkylating agents, such as cyclophosphamide (CY) and busulfan (BU), as well as other drugs such as 5-fluorouracil (FU), hydroxyurea (HU), and L-phenylalanine mustard (L-PAM) have been studied in terms of their short- and long-term effects on hemopoietic tissue (Fried and Johnson, 1968;

Fried *et al.*, 1977; Hays *et al.*, 1982; Santos and Owens, 1969, Santos and Tutschka, 1974; Tutschka and Santos, 1977; Morley and Blake, 1974; Boggs and Boggs, 1980; Sensenbrenner *et al.*, 1968; Botnick *et al.*, 1978; Brown and Carbone, 1971; Van Zant, 1984; Hodgson *et al.* 1975, 1982).

The majority of these reagents can be classified as antineoplastic, chemotherapeutic drugs, and therefore we should be aware of their potential to cause late complications in therapy. They have been shown to have severe adverse effects on the stem cell compartment if not administered in therapeutic doses. It is this very effect, on the hemopoietic tissue, that has stimulated their use in host preparation, as a means of replacing or reducing the requirements for irradiation.

Busulfan (BU) Treatment

BU is used almost exclusively for the treatment of myeloproliferative disorders, especially chronic myelogenous leukemia (CML). Its use requires judicious care since, if overprescribed, it can lead to irreversible bone marrow failure. Busulfan was originally discovered when the effects of sulphonic acid esters on tumor growth were being evaluated. At low doses, BU acts by selectively depressing granulocytopoiesis. In slightly higher doses, platelet and erythroid elements may be affected, with a resultant pancytopenia developing.

Udupa *et al.*, (1972), using a murine model suggested that the target cell populations of BU treatment are noncycling cells, thus possibly explaining the observation of a slow recovery rate of CFU-S after BU administration. Morley *et al.* (1976) concluded from their studies that the effect of BU is primarily on the CFU-S and not the stromal cells. When BU was given repeatedly at short intervals for a limited time, it resulted in marrow aplasia and subsequent peripheral blood pancytopenia several months later. Hays and her colleagues (Hays *et al.*, 1982) reported that BU treatment causes a "prolonged and apparently permanent injury to the bone marrow". In addition, they found a moderate to marked reduction in marrow CFU-S and CFU-GM that remained for as long as 18 months post treatment. Morley *et al.*, (1975) and Hellman *et al.*, (1978) concluded that BU affects stem cells directly, as evidenced by failure of CFU-S from BU-treated mice to self-renew and reconstitute hemopoiesis in irradiated normal recipients. Interestingly, however, irradiated BU-treated mice would not allow normal hemopoietic cells to fully engraft, suggesting damage to the microenvironment. Hays and colleagues postulated that the repopulation of irradiated BU-treated mice, evidenced by Morley, was due in part to the outgrowth of stromal elements within the donor inoculum. Research in this area is still ongoing. Side effects of BU treatment include increased risk of cataract formation, pulmonary fibrosis, and premature graying as a consequence of damage to melanocytes (Botnick

et al., 1978).

Cyclophosphamide (CY) Treatment

CY (5 mg/kg), if given intermittently, appears to cause damage to hemopoietic stromal function to the extent that there is no significant recovery for as long as six weeks post-administration (Fried *et al.*, 1977). CFU-S potential in these same hosts, after an initial decline in numbers, returns to pretreatment levels by six weeks. The major problem with this study is the unrealistically high dosage used when compared to the typical human dose of 60-120 mg/kg of body weight. In the latter, no evidence of cumulative effects on stromal elements was found. However, Buckner *et al.* (1974) reported of adverse effects of CY on thrombopoiesis.

5-Fluorouracil (FU) Treatment

FU appears to selectively kill rapidly dividing cells in various hemopoietic lineages until the surviving cells are those with a pluripotent potential and hence slower turnover. This view, advocated by Hodgson *et al.*, (1982), is supported by Van Zant (1984), who proposes that the reason for "... the delay in spleen colony growth caused by FU-treated cells is that primitive stem cells surviving FU are unable to directly initiate colony growth. Rather, the population undergoes developmental maturation, giving rise to a cohort of cells capable of spleen colonization and

growth". Van Zant then provides evidence that this is, indeed, correct. FU, it appears, is selectively more toxic to a population of older stem cells, than to younger ones. The sparing effect on the more primitive subpopulations is evidenced indirectly by a 100-fold increase in CFU-S colonies derived from FU-treated marrow cells. This effect on stem cells was shown to be dose dependent, both *in vitro* and *in vivo*.

Hydroxyurea (HU) Treatment

Studies by Hodgson *et al.*, (1975), support an initial observation by Sinclair, (1967) that HU affects cycling CFU-S, by acting as a synchronizing agent. This allows CFU-S in the S (synthesis) phase of their growth cycle to be collected *in vivo*. Hodgson assumes that HU kills cells in S phase by inhibiting DNA synthesis while permitting cells in other phases to continue in cycle and accumulate at the G₁/S boundary. When the HU concentrations drop, the accumulated cells move into S.

The drugs cited in the above section, therefore, have a variety of effects on the proliferative capacity of various stem cell lineages and stromal microenvironments. Recently, the clinical use of alkylating agents has been associated with tumor induction (Botnick *et al.*, 1978).

So far we have examined two different means by which one can establish hemopoietic engraftment across MHC barriers. The first, the radiation model, although

successful under certain conditions, still is attended by a variety of complications. Most notable is the fact that TBI increases the incidence of GVHD and also gives rise to the subsequent development of malignancies. Secondly, the cytotoxic drug approach is far too nonspecific in its mode of action, inflicting, in some situations, irreversible damage to the hemopoietic environment.

Perhaps the simplest approach to solving or reducing the complications inherent in the above mentioned models, comes from studies which will be considered next.

C. Parabiont Model

Drell and Wegmann (Drell *et al.*, 1979a, 1979b; Wegmann *et al.*, 1980) describe, in some detail, their findings of a parabiotic model of hemopoietic engraftment. Basically, these authors confirmed and extended an initial observation by Rubin (1959), of an unexpected 50% survival rate in parabiosed mice differing in their MHC haplotypes. They showed that in the H-2 incompatible strain combination of DBA mice, parabiosed to (DBA x C3H)F₁ hybrid mice, after an initial chimeric state, both parental and F₁ hybrid partners displayed a complete takeover of their red and white blood cell compartments by cells of the DBA phenotype. Interestingly, if spleen cells from either of the parabionts are removed and reexposed to C3H or third party alloantigens, either *in vitro* or upon adoptive transfer *in vivo*, they show virtually normal reactivity (Shaw *et al.*,



1974; Drell *et al.*, 1979a, 1979b). Later, these investigators found that an antibody present in the DBA mice parabiosed, to the (DBA x C3H)F₁ hybrid, was specific for antigens present on cells of some hemopoietic lineages. This antibody was cytotoxic *in vivo* and *in vitro* and reacted with an antigen encoded by a gene(s) linked to the left hand (K-I) end of the H-2K^b haplotype (Drell *et al.*, 1979a). These observations are reminiscent of a particular set of earlier experiments. Fox *et al.*, (1962) reported on a chromosome marker study that suggested that 10⁶ C57BL spleen cells injected into (C57BL x CBA(T6))F₁ hybrids repopulated the spleen completely, and remained for a period of at least 60 days. In contrast, chimerism in the marrow was only temporary. Of further interest was the finding that if the CBA(T6) partner was used as the source of donor cells, no splenic takeover was seen. Later, Batchelor and Howard (1965) found that hemopoietic chimerism could be achieved by the pretreatment of (C57BL x A)F₁ hybrids with uncharacterized C57BL anti-A antibody followed by 10⁶ C57BL spleen cells. Taken together, these findings support the possibility that GVHD could possibly be avoided by somehow selecting the proper combination of not only the donor cells but also the anti-host antibody.

D. Suppressor Cell Involvement in the Maintenance of Tolerance

In their parabiont studies, Drell *et al.*, (1979c) could not find any evidence for the presence of suppressor cells.

However, other investigators using allogeneic bone marrow chimeras prepared with total lymphoid irradiation have shown these chimeras to be specifically unresponsive when subsequently tested against both recipient and donor strains in an MLR assay (Slavin *et al.*, 1977). They postulated and went on to show the presence of antigen-specific donor-type suppressor cells that were able to inhibit the MLR of normal donor-type spleen cells against recipient-type and third-party stimulator cells (Okada *et al.*, 1983). Waer *et al.*, (1984) reported of an apparent association between TLI-irradiation protocols that gave rise to the successful engraftment of allogeneic bone marrow and the presence of nonspecific suppressor cells in the spleen. It must be mentioned, that it would be difficult to draw any conclusions between these studies and Drells' work, since in the latter situation no irradiation was used. Nonetheless, further evidence exists which describes a naturally occurring suppressor cell population in the bone marrow of normal adult mice (Bennett *et al.*, 1978; Bennett and Mitchell, 1980). An interesting observation that Strober (1984) made with regards to this population of suppressor cells, is that they have also been identified in other sites of "intense hematopoiesis in the rodent", for example in spleens of adult mice which had received TLI, Sr'', BCG, or cyclophosphamide. Incidentally, these suppressor cells are not found in the spleens of normal adult mice, unless the mouse has undergone one of the above mentioned hemopoietic

stimulating treatments (Oseroff *et al.*, 1984).

Strober (1984) in a recent review, proposed that a population of non-specific suppressor cells in the spleens of adult mice given TLI before marrow transplantation are capable of preventing the development of cytotoxic T cells, while allowing the emergence of a population of antigen-specific suppressor T cells after marrow transplantation. These latter suppressor cells, of host origin, are presumed to block the generation of cytolytic T cells directed against host cells. In a similar manner, donor-derived antigen-specific suppressor cells may possibly prevent graft-*versus*-host disease by preventing the development of cytolytic cells directed against the host.

Let us now consider the research project.

E. Antibody-Facilitated Model: Introduction to The Research Project

AF chimeras are a natural extension of the ideas which were generated out of the parabiont studies of Drell and Wegmann (Drell *et al.*, 1979a, 1979b; Wegmann *et al.*, 1980). Their discovery of complete hemopoietic takeover of both parabiont partners, and the subsequent appearance and persistence of a circulating anti-host antibody, suggested that this could be simulated by the injection of F₁ hybrids with parental donor spleen cells along with a monoclonal anti-host antibody. Preliminary results did indeed reveal this hypothesis to be correct.

This project involved determining the optimal cellular and mAb requirements for obtaining a successful hemopoietic engraftment of the recipient, while avoiding or minimizing the effects of GVHD. The cellular requirements involved determining both the cell type, bone marrow or spleen, and cell numbers, while the mAb requirements concentrated on amount, class, and specificity. Equally important was the establishment of a protocol for the administration of cells and mAb.

The lack of adequate quantitation of hemopoietic takeover by means of an existing qualitative Gpi electrophoretic assay was resolved with the introduction of a far more sensitive, rapid and reliable method.

Analysis of the effects of the mAbs on the recipients hemopoietic tissue were addressed in a variety of both *in vitro* and *in vivo* assays. Similarly, hemopoietic reconstitution of long-term AF chimeras was examined using both *in vitro* long-term bone marrow cultures and methyl cellulose colony cultures and *in vivo* by means of the CFU-S assay.

The findings, that complete hemopoietic takeover between semiallogeneic adults can be accomplished by the administration of antihost MHC monoclonal antibody and donor stem cells, as well as the chimeric characteristics of these animals once engrafted will now be presented.

VI. Materials and Methods

Mice

BALB/cCR(BALB, H-2^d, *Gpi-1a*), DBA/2J (DBA, H-2^d, *Gpi-1a*), C3H/HeJ (C3H, H-2^k, *Gpi-1b*), CBA/CAJ (CBA, H-2^k, *Gpi-1b*), (BALB/cCR x C3H/HeJ)F₁, ((BALB x C3H)F₁, H-2^{d/k}, *Gpi-1a/b*) and (DBA/2J x C3H/HeJ)F₁, ((DBA x C3H)F₁, H-2^{d/k}, *Gpi-a/b*) were originally obtained from Jackson Laboratory, Bar Harbor, MAINE, and maintained as pedigree lines at the Laboratory Animal Breeding Unit of the University of Alberta (Ellerslie, Alberta, Canada.) The H-2 haplotypes of these strains are shown schematically in Table 1.

Monoclonal Antibodies

Anti-H-2K^k (11-4.1) and anti-H-2I-A^k (10-3.6) hybridomas were obtained from the Salk Cell Distribution Centre, La Jolla, CALIFORNIA, and from American Type Culture Collection, Rockville, MARYLAND. These hybridomas originated in the laboratory of Dr. L. A. Herzenberg (Oi *et al*, 1978). Monoclonal antibodies produced are of the IgG2a subclass and were produced as ascites fluid from hybridoma-bearing BALB mice. Each batch of mAb-containing ascites fluid was tested in an *in vitro* competitive binding assay with the appropriate ¹²⁵I-labeled antibody. ¹²⁵I-mAb (10⁵ cpm) was mixed with graded amounts of the ascites and added to 2 x 10⁷ C3H (target) and/or BALB (control) spleen cells (Raghupathy *et al.*, 1981). The 50% inhibiting dose of the

Table 1

H-2 and *Gpi* genotypes of mouse strains and the regions of the H-2 major histocompatibility complex recognized by the monoclonal antibodies used in these studies.

STRAIN ¹	K	I-A	I-E	D	<i>Gpi</i>
DBA/2J	d/d	d/d	d/d	d/d	a/a
BALB/cCR	d/d	d/d	d/d	d/d	a/a
CBA/CAJ	k/k	k/k	k/k	k/k	b/b
C3H/HeJ	k/k	k/k	k/k	k/k	b/b
(DBA/2J x C3H/HeJ)F ₁	d/k	d/k	d/k	d/k	a/b
(BALB/cCR x C3H/HeJ)F ₁	d/k	d/k	d/k	d/k	a/b
<u>MONOCLONAL ANTIBODIES²</u>					
Anti-H-2K [*] (11-4.1)	k	-	-	-	
Anti-H-2I-A [*] (10-3.6)	-	k	-	-	

¹Reference: Klein, 1982.

²IgG2a subclass.

ascites was compared with a reference batch of ascites of known activity.

The procedure used to determine the amount of specific mAb necessary to produce AF chimeras is as follows: Ascites fluid was put through a Protein A-Sepharose column, and the eluted antibody was labeled with ^{125}I , and then purified by adsorption and elution from glutaraldehyde-fixed target C3H spleen cells. Labeling resulted in 600 μg of specific IgG containing 3×10^7 cpm. In competitive inhibition studies, the addition of 0.3 microliter (μl) of ascites resulted in 50% inhibition of binding of 5×10^4 cpm of the ^{125}I -mAb preparation on target C3H spleen cells. Therefore, 0.3 μl of ascites equals 0.5 μg of specific IgG. This was related back to the amount (0.25 ml) of ascites used to produce AF chimeras. The subsequent estimate of specific IgG injected is 416 $\mu\text{g}/\text{mouse}$.

Radioiodination of Immunoglobulins

The antibodies used in the competitive binding radioimmunoassay were ^{125}I -labeled by the chloramine T method of Greenwood et al (1963). Labeling was performed at a molar ratio of one iodine atom to one IgG molecule. 5-millicuries of radiolabeled sodium iodide (New England Nuclear, Lachine, QUEBEC) was added to a 5 milligram (mg) solution of the immunoglobulins in PBS. 50 μl of chloramine T (2 mg/ml) was subsequently added to this mixture and the

oxidation reaction allowed to continue for two minutes (min) at room temperature. To prevent further oxidation, the mixture was neutralized with 60 μ l of sodium metabisulfite (6 mg/ml). 10 μ l of 1% potassium iodide was then added and the solution dialyzed against saline to remove free iodine.

Ammonium Sulphate Precipitation

MABs used in the preparation of AF chimeras in later experiments were precipitated with ammonium sulphate. 200 ml of raw ascites was added to 100 ml of cold phosphate buffered saline (PBS), mixed, and allowed to stand on ice. 300 ml of a cold, supersaturated solution of ammonium sulphate (Fisher Scientific Co. Cat. No. A-7023, Fair Lawn, NEW JERSEY) was then slowly added. The complete mixture was allowed to stand undisturbed on ice for a minimum of 1 hr.

The cooled mixture was spun for 30 min in 250 ml polycarbonate bottles at 7500 - 9000 rpm in a Sorval Superspeed Model RC2-B refrigerated centrifuge. The supernatant was discarded and the pellet resuspended in 60 ml PBS. Exactly 40 ml of a 100% saturated ammonium sulphate solution was then added slowly with continuous stirring and the mixture allowed to stand on ice for a minimum of one hour. This mixture was then centrifuged at 7500 - 9500 rpm for 30 min. The supernatant was discarded and the pellet resuspended completely in 50 ml normal saline. This was then dialyzed in three changes of normal saline, spun at 9,000 -

10,000 rpm to remove fibrin clots, aliquoted and stored at -70°C . Specific activity was tested in an *in vitro* competitive binding radioimmunoassay, described above.

Preparation of Antibody-Facilitated (AF) Chimeras

AF chimeras were prepared by the intravenous (iv) administration of donor parental stem cells accompanied by antihost mAb into otherwise untreated F₁ recipients (Figure 1). (Wegmann *et al*, 1980). Adult BALB or DBA mice provided donor stem cells, derived from either spleen, bone marrow (BM), or T cell-depleted BM. Spleens were excised, pressed through a stainless steel screen, and washed in Leibovitz medium. BM cells were obtained by flushing Leibovitz media through tibias and femurs of donor mice.

To obtain T cell-depleted BM cells (αBM), single cell suspensions from the BM were treated for a one hour period in a two-step cytotoxicity assay with a 1:5000 dilution of monoclonal anti-Thy 1.2 (New England Nuclear, Boston, MASSACHUSETTS), followed by a 1:6 dilution of agarose-adsorbed guinea pig complement (GPC) (Flow Laboratories, McLean, VIRGINIA).

AF chimeras were produced by the injection of donor stem cells (spleen, BM, or αBM) accompanied by anti-H-2K^b or anti-H-2I-A^b ascitic mAb (approximately 416 μg of specific IgG). Depending on the specificity of mAb, AF chimeras are referred to as anti-H-2K^b AF chimeras or




Figure 1. Antibody-Facilitated Chimeras protocol.

anti-H-2I-A^k AF chimeras. AF chimeras were maintained on 325 mg/liter Terramycin (Pfizer Canada, Montreal, QUEBEC) in their drinking water.

Hematocrit determinations

Mice were placed under light anesthesia with Penthrane (Methoxy fluorane, N.F., Abbott Laboratories, Montreal, QUEBEC) and bled from the retro-orbital sinus through heparinized microhematocrit tubes (Dade B4415-30, Miami, FLORIDA). These tubes were then plugged at one end with Critoseal (Clay-Adams, NEW JERSEY) and spun in a hematocrit centrifuge for 10 min (Model MB, International Equipment Co., Needham, MASSACHUSETTS). The percent hematocrit was determined using a microhematocrit capillary tube reader (Lancer, St. Louis, MISSOURI).

Quantitation of Chimerism by the Gpi assay

Heparinized blood, collected from normal P₁ and F₁ mice, was spun at 300 g for 10 minutes, and the cell pellets resuspended in phosphate buffered saline (PBS) and the cells washed three times in PBS. Artificial mixtures were prepared by mixing varying numbers of P₁ and F₁ cells. Cell lysates were run in starch gel electrophoresis and GPI activity visualized using the nitrocellulose overlay staining technique of Peterson (1978). GPI is a dimeric molecule and is expressed in inbred strains of mice in either of two

electrophoretically distinct forms: a slower migrating protein encoded by the glucose phosphate isomerase - 1a (*Gpi-1a*) gene and a faster migrating protein encoded by the (*Gpi-1b*) gene. Genetic hybrids between these two types (*Gpi-1a/b*) express both parental forms of the enzyme as well as a heterodimer protein with intermediate mobility (Figure 2). Donor GPI content of the artificial cell mixtures was measured by scanning the nitrocellulose filters with a densitometer (Camag, Muttentz, SWITZERLAND.). A Hewlett-Packard Model 3390A Reporting Integrator (Palo Alto, CA) was used to obtain a quantitative value for each sample, which was converted to a ratio of fast band to slow band activity. These values were plotted to generate a standard curve (see Figure 3). that was used to determine the donor GPI content of unknown samples. Using this protocol, as few as 5% P₁ cells can be detected in an artificial mixture of P₁ and F₁ cells.

Separation of Peripheral Red and White Blood Cells

Studies have indicated that red and white cell chimerism in the peripheral blood are essentially equivalent to each other (Gambel *et al.*, 1984). Therefore, in most cases, the percentage of chimerism reported reflects unfractionated peripheral blood sampling. In addition, peripheral red and white cell chimerism was monitored separately in some groups. A murine white cell density gradient (specific gravity 1.09) was prepared using Percoll




Figure 2. Electrophoretic migration patterns of glucose phosphate isomerase isozymes.




Figure 3. Gpi standard curve . Comparison of % P₁ cells in an artificial mixture of P₁ and F₁ cells using the ratio of fast to slow band. For details of the Gpi assay see Materials & Methods. Results are given as mean $\pm$ standard deviations. 5 different samples of each mixture.

(Pharmacia, Uppsala, SWEDEN). Peripheral blood was obtained from the tail vein and collected into heparin-containing PBS (1% v/v). The cell suspension was then washed twice in PBS and layered on the Percoll gradient in 15 ml conical tubes and centrifuged at 300 g for 30 min at room temperature. The white cells at the interface and the red cells in the pellet were collected independently of one another, washed, and prepared for GPI isozyme analysis.

Effects of mAbs on Pluripotential Stem Cells

The spleen colony forming unit (CFU-S) assay of Till and McCulloch (1961) was utilized to determine the effects of anti-H-2K^b and anti-H-2I-A^b mAbs on pluripotential stem cells. Briefly, recipient mice were irradiated with 950 R (Cesium¹³⁷ source, Gamma Cell 40, Atomic Energy of Canada, Ottawa, CANADA) on day -1, and injected iv with 10⁵ syngeneic donor BM cells on day 0. Donor BM cells were pretreated with mAbs either *in vitro* or *in vivo* before injection into syngeneic, irradiated recipients, as described below. CFU-S were counted as macroscopic spleen colonies 11-12 days later.

For *in vitro* pretreatment, 10⁷ BM cells from BALB, C3H or (BALB x C3H)F₁ mice were incubated with a 1:10 dilution of either anti-H-2K^b, anti-H-2I-A^b, or control P1.1 mAb, an IgG2a mAb of no known specificity, for 60 min at 4° C. The cells were washed and then incubated with a 1:6 dilution of GPC for 30 min at 37° C and finally washed twice.

For *in vivo* pretreatment, BALB, C3H or (BALB x C3H)F₁ mice were injected iv with anti-H-2K^b, anti-H-2I-A^b or control P1.1 mAb. The amount of mAb injected was equivalent to that necessary for the production of AF chimeras. After 48 hours (hrs), single cell suspensions were prepared from the BM of each treatment group and then 10⁶ BM cells were injected into irradiated syngeneic recipients and CFU-S were counted as described above.

Bone Marrow Fractionation

Femurs from long-term AF chimeras were fractionated to yield three distinct subpopulations of bone marrow cells (Allalunis *et al*, 1983) as shown in Figure 4. Femurs were excised and subsequently treated as follows: initially, they were flushed with 3 ml of Leibovitz medium twice and the resultant cells, representing fraction I (medullary cavity), were collected and stored on ice. Crude collagenase Type 1A (Sigma Cat. No. C-9891, St. Louis, MISSOURI) was then added to the medium (1 mg/ml vol) and the femur flushed continuously for 10 - 12 min; the resultant cells, fraction II (endosteal fraction) were then resuspended and stored on ice. Fraction III or the compact fraction was obtained by breaking the femur into little pieces, less than 2 millimeters (mm) in size, in a petri dish containing media with collagenase. The mixture was vigorously agitated every 2 min over a 15 min period. The bone fragments were allowed




Figure 4. Bone marrow fractionation protocol.

to settle and the supernatant transferred to a tube and centrifuged. The resultant cells were saved. Cells of all three fractions were then analyzed in the Gpi assay to determine their origin.

Long-Term Bone Marrow Cultures

Long-term bone marrow cultures were established using the method described by Dexter *et al.*, (1977b) and modified by Greenberger (1978). The contents of a single femur were flushed with 10 ml of RPMI 1640 containing 20% horse serum (Flow Laboratories, McLean, VA), 10^{-7} M hydrocortisone sodium succinate (Upjohn Company, Don Mills, ONT.), and penicillin plus streptomycin (1ml/L v/v; Gibco Laboratories, Grand Island, NY). Cultures were maintained in 25 cm² tissue culture flasks (Corning Glass, Corning, NY) at 33° C in 5% CO₂. They were fed weekly by replacing 5 ml of old media with 5 ml of fresh media. The non-adherent cell population was collected by centrifuging the supernatants of the culture flasks; the adherent cell layer was recovered after a 5 minute incubation of the contents of the flask at 37° C with stock trypsin ethylenediamine tetraacetic acid (EDTA)(Gibco). Adherent and nonadherent cells were then analyzed in the Gpi assay see Figure 5.




Figure 5. Gpi analysis of long-term bone marrow culture adherent and nonadherent cells.

Methyl Cellulose Cultures

Stem and progenitor cell activity of BM or spleen cells was tested in a methyl cellulose colony assay (Worton, 1969). Briefly, 7.5×10^4 bone marrow (BM) cells/ml or 10^4 spleen cells were suspended in a final volume of 1 ml containing 0.4 ml of 2.1% stock methyl cellulose (4000 Centipoises; Sigma Chemicals, St. Louis, MO), 0.3 ml of stock fetal calf serum (Flow), 0.2 ml Alpha medium (Gibco) or Iscove's modified Dulbecco's medium (Gibco) and 0.1 ml pokeweed mitogen-stimulated spleen conditioned medium (SCM), a source of colony stimulating factor (Johnson, 1977). Erythropoietin (EPO), prepared as described in Erythropoietin Production, was added to each culture at a concentration of 20 μ l/dish. The cell suspension was layered in 35 x 10 mm culture dishes (Lux Scientific, Catalog No. 5221-R, Miles Laboratories, Naperville, IL) at 1 ml/dish and incubated at 37° C in 10% CO₂ for 8 to 12 days. Colonies were individually picked by micropipette, frozen overnight at -20° C and loaded directly onto a starch gel and analyzed in the Gpi assay to determine their Gpi phenotype and hence P_i or F_i derivation; 60-90 randomly picked colonies were analyzed from each culture of spleen or bone marrow cells in order that chimeric ratios could be calculated, see Figure 6.




Figure 6. Technique for genotyping individual *in vitro* methyl cellulose bone marrow/spleen hemopoietic colonies.

2.1% Methyl Cellulose W/W

Stock methyl cellulose was prepared as follows: 84 gm of methyl cellulose was weighed and autoclaved in a six liter flask. A large four inch magnetic stirring bar and 2.5 L of double distilled water were also autoclaved. The water was heated to 90° C before use. To the 84 gm of autoclaved methyl cellulose powder 1.958 L of autoclaved double distilled water was added. The flask was then placed over the burner and allowed to boil until all the powder dissolved. This mixture was then stirred for approximately three hours or until it had cooled to room temperature. At that time 1.958 L of double strength alpha medium at room temperature was added. The flask was sealed and inverted several times to ensure good mixing, then placed in the cold room and immersed in ice. Stirring was continued overnight or until the solution was clear. The solution was then aliquoted into 100 ml bottles and allowed to sit at room temperature for eight days. Contaminated bottles were discarded and the remainder frozen at -20° C.

Spleen Conditioned Medium

SCM used in the methyl cellulose assay was prepared as follows: 2×10^7 spleen cells from 10 week old (BALB x C3H)F₁ mice were washed three times in RPMI 1640 media and added to 900 ml RPMI 1640 containing Penicillin-Streptomycin antibiotics, 50 ml of a 1:15 dilution of pokeweed mitogen

(Gibco Laboratories, Grand Island, NEW YORK) and 50 ml heat-inactivated fetal calf serum (Gibco Laboratories, Grand Island, NEW YORK). The cultures were placed in large 1 l glass flasks and incubated at 37° C in 10% CO₂ for one week, after which time the supernatant was harvested and concentrated ten-fold through an Amicon Diaflo YM10 76mm ultrafiltration membrane (Amicon, Oakville, ONTARIO). The SCM was then aliquoted and frozen at -70° C. Prior to use in the colony assay the SCM was filtered through a 45 µ Millex-HA ultracleaning filter unit (Millipore Corporation, Bedford, MASSACHUSETTS) and diluted to a final working concentration of 1:1.

Erythropoietin Production

EPO used in the methyl cellulose assay was either produced in our laboratory or purchased from The Terry Fox Cancer Research Institute, Vancouver, BRITISH COLUMBIA. It was produced in our laboratory by irradiating 10-16 week old (BALB x C3H)F₁ mice on day -1 with 700 rads and injecting them intraperitoneally on day 0 with 60 mg/kg body weight of phenylhydrazine hydrochloride (Sigma P-7126, St. Louis, MISSOURI) in saline. Blood was collected, in heparinized tubes on day 10 and the plasma aliquoted and frozen at -70° C. Prior to use it was passed through a 45 µ Millex-HA ultracleaning filter unit and titrated to determine which concentration best supported erythroid colony growth.

Peritoneal Macrophages

Macrophages were harvested from the peritoneal cavity of AF chimeras similarly to previously described techniques (van Furth, 1968, 1970; Thompson, 1970). Mice were killed by gentle cervical dislocation in such a manner as to prevent contamination of the peritoneal cavity with blood. Three ml of Puck's saline were injected into the peritoneal cavity using a syringe. The abdomen was gently massaged to ensure adequate lavage of the peritoneum. A tiny hole was cut in the peritoneal wall and the fluid removed with a Pasteur pipette and centrifuged at 450 g for 10 minutes at 4°C. The resulting pellet was resuspended in 5 ml of Dulbecco's medium (Gibco) containing 0.5 ml of a lymphokine solution and 3 µg of lipopolysaccharide (Difco). (The lymphokine solution was prepared by culturing popliteal lymph node cell suspensions (2×10^6 cells/ml) with protein purified derivative (100 µg/ml; Difco); the lymph node cells were recovered from mice that had been injected in the footpads 7-9 days previously with complete Freund's adjuvant (Difco) emulsified 1:1 in saline.) This mixture was transferred to 100 mm culture plates (Corning) and incubated at 37°C in 10% CO₂ for 6 to 8 hours. After the nonadherent cells were removed, the adherent cells were recovered by vigorous pipetting of the plate with PBS-EDTA (Gibco). The harvested cells were lysed by freeze/thawing and subsequently analyzed in the Gpi assay.

VII. Results

A. Production of Antibody-Facilitated Chimeras

Production of anti-H-2K^b Antibody-Facilitated Chimeras With Spleen Cells or Bone Marrow Cells or Both

DBA → (DBA x C3H)F₁ Hybrid Strain Combination

Previously it had been shown that semiallogeneic chimeras could be produced by the injection of 0.25 ml of anti-H-2K^b mAb one day before the injection of 10⁶ untreated DBA/2J spleen cells into (DBA x C3H)F₁ hybrid mice (Wegmann *et al.* 1980). Injection of irrelevant antibody or of cells alone did not lead to any takeover.

In an attempt to reduce the cell dosage required for takeover, we decided to use bone marrow as a source of stem cells, since the hemopoietic potential of bone marrow tissue is much greater than that of the spleen (Lord, 1983). The simultaneous injection of 2 x 10⁷ untreated DBA BM cells along with 0.25 ml anti-H-2K^b mAb into age- and sex-matched (DBA x C3H)F₁ hybrids leads to > 95% takeover by donor cells, at eight weeks, as measured in a Gpi assay of the peripheral blood (Table 2). As before, injection of cells alone did not give rise to takeover.

To examine if any synergistic or additive effect would be seen, a combination of 2 x 10⁷ DBA/2J BM cells plus 10⁶ DBA/2J spleen cells were administered

Table 2

Production of Anti-H-2K^k Antibody-Facilitated Chimeras with Spleen and/or Bone Marrow Cells. DBA/2J → D2C3F₁.

DONOR	CELL SOURCE ¹	mAb ²	RECIPIENT ³	N	%DONOR CELLS ⁴
DBA/2J	10 ⁶ SC	αK ^k	D2C3F ₁	6	>95
DBA/2J	10 ⁶ SC	-	D2C3F ₁	3	0
DBA/2J	2 x 10 ⁷ BMC	αK ^k	D2C3F ₁	3	>95
DBA/2J	2 x 10 ⁷ BMC	-	D2C3F ₁	3	0
DBA/2J	10 ⁶ SC + 2 x 10 ⁷ BMC	αK ^k	D2C3F ₁	25	>95
DBA/2J	10 ⁶ SC + 2 x 10 ⁷ BMC	-	D2C3F ₁	5	0

¹Spleen cells (SC) or bone marrow cells (BMC).

²416 μg of anti-H-2K^k (αK^k) (11-4.1) monoclonal antibody (mAb).

³D2C3F₁ = (DBA/2J x C3H/HeJ)F₁.

⁴Percentage of DBA/2J donor cells in D2C3F₁ host peripheral blood as determined by the glucose phosphate isomerase assay. Determinations were made 8 weeks postinjection.

simultaneously with the mAb. The kinetics of takeover showed no difference as compared to groups which received spleen cells and mAb or BM cells and mAb.

BALB → (BALB x C3H)F, Hybrid Strain Combination

After having worked out the minimal cellular requirements necessary for takeover, we decided to extend the model to another strain combination. The BALB → (BALB x C3H)F, combination was chosen, since attempts to parabiose these strains leads to parabiosis intoxication and death (Drell, 1979a).

5 x 10⁷ spleen cells or 2 x 10⁷ BM cells from BALB mice were injected along with anti-H-2K^k mAb into (BALB x C3H)F, recipients (Table 3). The time course of donor engraftment was similar to that seen in the DBA/2J → (DBA/2J x C3H/HeJ)F, model. This time course was also comparable to the takeover seen in control radiation chimeras. Once again, injection of cells alone did not lead to any chimerism.

Production of anti-H-2K^k and anti-H-2I-A^k Antibody-Facilitated Chimeras with anti-Thy 1.2 Treated Bone Marrow

To determine the optimal dosage of anti-Thy 1.2 treated BM (αθBM) cells needed for producing donor chimerism in the host, various numbers of BALB αθBM cells and a constant amount (approximately 416 μg of specific IgG, subclass IgG2a) of anti-H-2K^k ascitic mAb were injected into (BALB x C3H)F, recipients.

Table 3

Production of Anti-H-2K^k Antibody-Facilitated Chimeras with Spleen and/or Bone Marrow Cells. BALB → CC3F₁.

DONOR	CELL SOURCE ¹	mAb ²	RECIPIENT ³	N	%DONOR CELLS ⁴
BALB/cCR	5 x 10 ⁷ SC	αK ^k	CC3F ₁	5	>95
BALB/cCR	5 x 10 ⁷ SC	-	CC3F ₁	5	0
BALB/cCR	2 x 10 ⁷ BMC	αK ^k	CC3F ₁	5	>95
BALB/cCR	2 x 10 ⁷ BMC	-	CC3F ₁	5	0

¹Spleen cells (SC) or bone marrow cells (BMC).

²416 μg of anti-H-2K^k (αK^k) (11-4.1) monoclonal antibody.

³CC3F₁ = (BALB/cCR x C3H/HeJ)F₁.

⁴Percentage of BALB/cCR donor cells in CC3F₁ host peripheral blood as determined by the glucose phosphate isomerase assay. Determinations were made 8 weeks postinjection.

2×10^7 α BM cells injected along with anti-H-2K^k mAb leads to > 95% takeover by 10 weeks (Table 4). The injection of 3×10^6 α BM cells and antibody could produce only a stable, partial chimerism. The use of 10^6 α BM cells plus antibody, 2×10^7 α BM cells alone, or with a non-specific mAb (P1.1) did not lead to any detectable chimerism.

In contrast to anti-H-2K^k AF chimeras, anti-H-2I-A^k AF chimeras exhibit only a partial chimeric state when a similar α BM cell dose of 2×10^7 is used (Table 5). Doubling the donor cell inoculum to 4×10^7 α BM cells, gave a comparable > 95% takeover pattern as seen with our anti-class I mAb. Increasing further the donor cell numbers to 6×10^7 α BM cells did not alter the degree of takeover, as monitored at 10 weeks. If α BM donor cells are injected alone or with control non-specific P 1.1 mAb no chimerism could be detected.

Time Frame for Donor Inoculum

Donor cells and antihost mAb do not need to be injected simultaneously to produce AF chimeras. In an effort to establish a time frame for the donor inoculum, we injected cells either two or five days before the mAb (day 0), or mAb five or seven days before cells (Figure 7). In these experiments (BALB x C3H)F₁ recipients were injected with 10^6 spleen cells plus 2×10^7 BM cells from BALB donors together with anti-H-2K^k mAb. The reason that spleen cells were used, is related to the fact that initially AF chimeras were

Table 4

Production of Anti-H-2K^b Antibody-Facilitated Chimeras with anti-Thy 1.2 Bone Marrow ($\alpha\Theta\text{BM}$) Cells.

$\alpha\Theta\text{BM}$ ¹	TREATMENT mAb ²	% DONOR CELLS/WEEKS ³		
		4	8	10
1 x 10 ⁶	αK^b	0	0	0
3 x 10 ⁶	αK^b	54(10)	63(15)	69(13)
2 x 10 ⁷	αK^b	75(10)	86(5)	>94
4 x 10 ⁷	αK^b	82(16)	>95	>95
2 x 10 ⁷	None	0	0	0
2 x 10 ⁷	P1.1	0	0	0

¹Percentage of BALB/cCR donor cells in (BALB/cCR x C3H/HeJ)F₁ host peripheral blood as determined by the glucose phosphate isomerase assay. Each value represents the mean (standard deviation) of 5 mice.

²BALB/cCR bone marrow cells treated with anti-Thy 1.2+ complement.

³CC3F₁ = (BALB/cCR x C3H/HeJ)F₁.

⁴416 μg of anti-H-2K^b (αK^b) (11-4.1) monoclonal antibody.

Table 5

Production of Anti-H-2I-A^k Antibody-Facilitated Chimeras with anti-Thy 1.2 Bone Marrow ($\alpha\theta$ BM) Cells.


$\alpha\theta$ BM ²	TREATMENT mAb ³	% DONOR CELLS/WEEKS ¹		
		4	8	10
2 x 10 ⁷	α I-A ^k	16(13)	58(6)	83(7)
4 x 10 ⁷	α I-A ^k	58(11)	>95	>95
6 x 10 ⁷	α I-A ^k	73(14)	>95	>95
2 x 10 ⁷	None	0	0	0
2 x 10 ⁷	P1.1	0	0	0

¹Percentage of BALB/cCR donor cells in (BALB/cCR x C3H/HeJ)F₁ host peripheral blood as determined by the glucose phosphate isomerase assay. Each value represents the mean (standard deviation) of 5 mice.

²BALB/cCR bone marrow cells treated with anti-Thy 1.2 + complement.

³416 μ g of anti-H-2I-A^k (α I-A^k) (10-3.6) monoclonal antibody.

TIME FRAME FOR AF CHIMERA PROTOCOL



mAb - ANTI-H2K^b (11-4.1)

CELLS - 10^8 SPLEEN CELLS + 2×10^7 BONE MARROW CELLS

Figure 7. Variation in the time frame for the establishment of Antibody-Facilitated Chimeras.

produced using spleen cells alone. Donor takeover was seen by 8 weeks post-injection of the cells, irrespective of whether the mAb was injected before or after the donor cell inoculum. The percentage of takeover as measured by the Gpi assay was greater than 95% in all mice (10 per group) tested.

B. *In vivo* and *in vitro* Effects of mAbs on Hemopoietic Tissue

Effects on Hematocrits and Buffy Coats

The effect of the intravenous administration of an anti-Class II (anti-H-2I-A^k) mAb into untreated recipients of various H-2 haplotypes is shown in Figure 8. Strains bearing the appropriate target antigens, namely the H-2^k haplotype, undergo a transient drop in their buffy coat levels. These levels return to normal by about 7-8 weeks. Their hematocrit levels also experience a transient decline with full recovery by 8 weeks. F₁ hybrids do not undergo as marked a drop in levels. BALB mice are not affected. Examination of mice prepared by the AF chimeras protocol, in this case using an anti-Class I mAb (anti-H-2K^k), reveals that a similar period of transient anemia exists, with recovery to normal pre-injection hematocrit levels by 6 weeks (Figure 9).




Figure 8. Effects of *in vivo* intravenous administration of anti-H-2I-A^k (10-3.6) monoclonal antibody on hematocrits and buffy coats of various strains. Values represent mean $\pm$ standard deviation of 10 mice/group. BALB = BALB/cCR; C3H = C3H/HeJ; CBA = CBA/CAJ.




Figure 9. Hematocrit determinations of AF Chimeras (BALB x C3H)F₁ . 2, 4, 6 and 8 weeks post-injection of anti-H-2K^k (11-4.1) mAb plus varying numbers of BALB donor BM cells. Each point represents mean $\pm$ SD of 5 mice /group.

Effects on the CFU-S Assay

in vitro and *in vivo* Effects With anti-H-2K^k and anti-H-2I-A^k mAbs

Since anti-H-2K^k and anti-H-2I-A^k mAbs assist donor cell repopulation, their effects on pluripotential stem cells were evaluated by the CFU-S assay. The presence of class I and class II molecules on CFU-S was examined directly by incubating BALB, C3H, or (BALB x C3H)F₁ BM cells with mAb and complement *in vitro*, then using the treated cells to repopulate irradiated syngeneic mice. Repopulation was attempted with 10⁵ treated or control cells (Table 6). Compared with control mAb (P1.1) anti-H-2K^k mAb pretreatment but not anti-H-2I-A^k mAb pretreatment reduced the number of CFU-S in recipient spleens. To determine the *in vivo* effects of these mAbs, BALB, C3H, or (BALB x C3H)F₁ mice were inoculated iv with anti-H-2K^k or anti-H-2I-A^k mAb at a dose equivalent to that required for AF chimeras production. After 48 hr, 10⁵ BM cells from the treated mice, which had received the mAb, were harvested and transferred to irradiated syngeneic recipients (Table 7). Both control mAb (P1.1)-treated and untreated mice served as control donor BM cell sources. In support of the *in vitro* findings, anti-H-2K^k mAb *in vivo* could almost completely inhibit the CFU-S potential of target BM from C3H or (BALB x C3H)F₁ mice. In contrast to the anti-H-2I-A^k mAb pretreatment *in vitro*, the *in vivo* administration of

Table 6

In Vitro Effects of Anti-H-2K^k and Anti-H-2I-A^k on CFU-S.

Target	CFU-S COLONIES/TREATMENT GROUP			
	Untreated	P1.1	αK^k	$\alpha I-A^k$
BALB/cCR	21(3)	19(3)	20(3)	21(4)
C3H/HeJ	15(3)	15(2)	2(1)	13(2)
(BALB/cCR x C3H/HeJ)F ₁	18(2)	20(3)	3(1)	17(2)

10⁵ bone marrow cells were pretreated *in vitro* with 1:10 dilution of IgG2a monoclonal antibody (untreated, P1.1, anti-H-2K^k (αK^k) or anti-H-2I-A^k ($\alpha I-A^k$) and complement and then were injected into syngeneic irradiated (950 rad) recipients (e.g. BALB/cCR BM → BALB/cCR 950 rad). Macroscopic spleen cell colonies (CFU-S) were counted 12 days later. Each value represents the mean (standard deviation) of 10 mice.

Table 7

In Vivo Effects of Anti-H-2K^k and Anti-H-2I-A^k on CFU-S.

Target	CFU-S COLONIES/TREATMENT GROUP			
	Untreated	P1.1	α K ^k	α I-A ^k
BALB/cCR	29(1)	29(1)	29(3)	20(1)
C3H/HeJ	15(1)	14(1)	2(2)	2(1)
(BALB/cCR x C3H/HeJ)F ₁	21(2)	22(2)	1(1)	11(1)

10⁶ bone marrow cells pretreated (48 hours) with 416 μ g IgG2a monoclonal antibody (untreated, P1.1, anti-H-2K^k (α K^k) or anti-H-2I-A^k (α I-A^k) were injected into syngeneic irradiated (950 rad) recipients (e.g. BALB/cCR BM $\rightarrow$ BALB/cCR 950 rad). Macroscopic spleen cell colonies (CFU-S) were counted 12 days later. Each value represents the mean (standard deviation) of 10 mice.

anti-H-2I-A^k mAb resulted in a marked decrease in the CFU-S capacity of relevant C3H or (BALB x C3H)F₁ mice. In all cases, the CFU-S capability of control BALB BM cells was not inhibited *in vitro* or *in vivo* by either mAb, which would be expected, because this is a strain which does not react with the mAb.

Ability of Long-Term Antibody-Facilitated Chimeras Sera to Inhibit CFU-S Appearance

Initial parabiont studies showed the presence of circulating cytotoxic antibodies directed against one of the parental haplotypes (Wegmann *et al.*, 1980). Therefore, we decided to examine the serum of established AF chimeras to determine if a similar antibody was present. The serum of (DBA x C3H)F₁ AF chimeras, 56 weeks post-transplantation of DBA BM cells along with anti-H-2K^k mAb, was used in an attempt to inhibit CFU-S colonies. Unlike the situation in the parabiont model, these sera had no effect on the reduction of CFU-S colonies when compared to the control anti-H-2K^k mAb (Table 8).

C. Hemopoietic Analysis and Genotyping of Antibody-Facilitated Chimeras

Red and White Blood Cell Chimerism

Examination of peripheral red and white cell chimerism shows that both cell classes are equivalent in numbers. This was evaluated in several groups of AF chimeras by separating

Table 8

Ability of Long-Term Antibody-Facilitated Chimeras Sera to Inhibit CFU-S Appearance.

TREATMENT OF C3H/HeJ BMC	CFU-S ²
AF Chimeras' sera (pooled)	14.0(3.4)
Anti-H-2K ^k mAb	2.2(1.1)
DBA/2J normal mouse serum	15.4(1.2)

¹DBA/2J → (DBA/2J x C3H/HeJ)F₁ AF chimeras at 56 wks post-transplantation.

²Mean number of colonies at day 12; n=12; mean (SD).

peripheral red and white blood cells on a Percoll gradient. AF chimeras produced using either anti-H-2K^k or anti-H-2I-A^k, as well as radiation chimeras, exhibited > 95% donor isozymes in both red and white cell fractions by 90 days postinjection of donor α BM cells (Table 9).

Long-Term Bone Marrow Cultures

Primary, long-term, bone marrow cultures were established from AF chimeras showing greater than 95% donor cells in their peripheral blood and bone marrow. These cultures were not reseeded with fresh bone marrow. Eight weeks after the initiation of culture, the adherent and non-adherent cells were analyzed by the GPI assay. As seen in Table 10, the nonadherent cells were greater than 95 % donor type, while the adherent cells were between 73 - 77 % of donor origin. This was unexpected, since the initial bone marrow inoculum used to start these cultures had been typed as being greater than 95 % donor. The most likely explanation is that a differential outgrowth of host connective tissue cells in the marrow is responsible for the appearance of the residual host population.

Genotyping of Peritoneal Macrophages

Macrophages derived from the peritoneal exudate of AF chimeras showing greater than 95 % peripheral donor blood cells were typed for GPI. It can be seen from Table 10 that the peritoneal exudate cells were approximately 90% donor.

Table 9

Peripheral Red and White Blood Cell Chimerism in Antibody-Facilitated and Radiation Chimeras.

TREATMENT			PERCENTAGE OF DONOR CELLS ¹	
$\alpha\theta\text{BM}$ ²	mAb ³	IRRADIATION	RED	WHITE
5 x 10 ⁷	αK^k	None	>95	>95
4 x 10 ⁷	$\alpha\text{I-A}^k$	None	>95	>95
2 x 10 ⁷	None	900 rad	>95	>95

¹Percentage of BALB/cCR donor cells in (BALB/cCR x C3H/HeJ)F₁ host peripheral blood separated on a percoll density gradient as determined by the glucose phosphate isomerase assay. Each value represents 5 mice examined >90 days post-injection of $\alpha\theta\text{BM}$ cells.

²BALB/cCR bone marrow cells treated with anti-Thy 1.2 + complement.

³416 μg of anti-H-2K^k (αK^k) (11-4.1) or anti-H-2IA^k ($\alpha\text{I-A}^k$) (10-3.6) monoclonal antibody.

Table 10

Percent Donor Phenotype of Adherent and Nonadherent Cells in Long-term Marrow Cultures and of Peritoneal Macrophages in Antibody-Facilitated Chimeras.

% DONOR TAKEOVER OF ANTIBODY-FACILITATED CHIMERAS ¹				
#	PERIPHERAL BONE MARROW BLOOD	CELLS	PERITONEAL MACROPHAGES	NONADHERENT ³ ADHERENT ³ CELLS CELLS
1	>95 ⁴ (10) ⁵	>95(10)	ND ⁶	>95(10) 75±2(10)
2	>95 (7)	>95(7)	90±9(7)	ND ND

¹Mice at 16 months post-transplantation.

²Using the Gpi assay.

³From 8 week long-term bone marrow cultures.

⁴Mean ± standard deviation.

⁵Number of mice/experiment.

⁶Not determined.

Contamination by host fibroblasts could account for the residual host component.

Residual Host Spleen, Lymph Node and Thymus Cell Populations

Gpi analysis of AF chimeras, 8 weeks to two years post-transplantation, revealed > 95 % donor takeover of both the peripheral blood (red and white cells) and bone marrow hemopoietic tissue. In contrast to these findings, examination of AF chimeric spleen, lymph node and thymic tissue revealed the existence of a substantial residual host cell population. Residual host cells constituted as much as 55 % of the spleen, 45 % of lymph nodes and 60 % of the thymus. These values are in sharp contrast to findings in radiation chimeras, which showed > 95 % takeover in the spleen and lymph nodes (Table 11). These studies were done in collaboration with SA McCarthy, Ph.D..

Correlation Between Proportions of Donor Cells in the Peripheral Blood and the Bone Marrow

Long-term (1-2 yrs) stable AF chimeras were analyzed for hemopoietic takeover. A comparison of the percent donor cells in the peripheral blood to the percent donor cells in bone marrow plugs shows a close, linear correlation (r value = 0.97 see Figure 10). This includes AF chimeras in the process of takeover, and those which did not achieve complete takeover as a result of the use of suboptimal treatment with mAb.

Table 11

Donor Cell Contributions to Spleen, Lymph Nodes, and Thymus.

AF Chimeras ¹	% BALB Cells ²			
	Peripheral Blood	Spleen	Lymph Nodes	Thymus
1	>95	75	nd ³	80
2	>95	70	nd	80
3	>95	45	55	65
4	>95	70	60	40

RAD Chimeras²

1	nd	>95	>95	nd
2	nd	>95	>95	nd
3	nd	>95	>95	nd
4	nd	>95	>95	nd

¹Individual BALB → (BALB x C3H)F₁ AF Chimeras.²Individual BALB → (BALB x C3H)F₁ Radiation (RAD) Chimeras.³Calculated from Gpi isozyme ratios, as described in Materials and Methods.⁴Not done.




Figure 10. Comparison of the percent of donor cells in peripheral blood and in the bone marrow of AF chimeras at various times post-transplantation. Each point represents values for individual animals.

**Comparison of the Percentage Donor Cells in Peripheral Blood
With the Percentage Donor Bone Marrow and Spleen-Derived
Methyl Cellulose Colonies**

Having established that a correlation exists between the percentage of donor cells in the peripheral blood and whole bone marrow of AF chimeras, we examined the chimerism of bone marrow colonies grown in methyl cellulose cultures. This was done in order to test the possibility that a residual population of host hemopoietic cells may exist, but at levels too low to be detected in a direct assay of bone marrow or spleen. The test is especially important in view of the existence of a substantial residual host population in the spleen of AF chimeras with greater than 95% donor cells in peripheral blood (McCarthy *et al.*, 1985). Between 60 and 90 colonies per AF chimera, containing granulocyte-monocyte, erythroid, megagaryocyte, and mixed lineages, were randomly picked 7 to 9 days after the initiation of culture and individually analyzed in the Gpi assay. The results are presented in Figure 11. Analysis reveals a direct correlation between the percent of donor-derived colonies and the percent of donor cells in the peripheral blood. Spleen cells were also cultured in methyl cellulose. The spleen-derived colonies showed a similar correlation with the chimerism of the peripheral blood cells (Figure 11; spleen colonies r value = 0.93; bone marrow colonies r value = 0.98).




Figure 11. Comparison of the percent of donor cells in peripheral blood and bone marrow-derived or spleen-derived methyl cellulose colonies. Each point represents the average percent donor chimerism of approximately 70-90 colonies of an AF chimera at various times post-transplantation. Determination by the Gpi assay.

Bone Marrow Fractionation

When the bone marrow of these AF chimeras was fractionated and analysed in the Gpi assay, > 95 % donor takeover was found in all three compartments. Fraction I, representative of the medullary cavity contents, GPI typed as > 95 % donor type. Fractions II and III, the endosteal and compact compartments respectively, were also found to be > 95 % of donor origin. These results are comparable to the complete repopulation seen in radiation chimeras (Table 12).

D. Allogeneic Antibody-Facilitated Chimeras Production

Using anti-H-2K^b mAb

Attempts to produce fully allogeneic AF chimeras (BALB → C3H) by administering various numbers of BALB αΘBM cells together with anti-H-2K^b mAb failed (Table 13). After 8 weeks (the time by which donor cell engraftment in radiation chimeras or P → F, AF chimeras could be detected), there was no evidence of donor cells in the allogeneic host's peripheral blood, even when the number of donor cells used was increased to 6×10^7 . Increasing the amount of mAb given, while maintaining a constant number of donor BALB αΘBM cells, also did not give rise to chimerism (Table 14).

Using anti-H-2K^b and anti-H-2I-A^b mAbs

Even when anti-H-2K^b and anti-H-2I-A^b mAbs were used simultaneously, chimerism could not be established across

Table 12

GPI Analysis of Peripheral Blood and Bone Marrow Fractions I, II, and III of AF Chimeras and Radiation Chimeras.

Exp	Treatment	FRACTION TESTED			
		Blood	I Medullary	II Endosteal	III Compact
1	anti-H-2K ^b	>95 ^a	>95	>95	>95
2	anti-H-2I-A ^b	>95	>95	>95	>95
3	900 rad ^c	>95	>95	>95	>95

^a2 x 10⁷ BALB BM cells into (BALB x C3H)F₁.

^b4 x 10⁷ BALB BM cells into CC3F₁, along with anti-H-2I-A^b mAb.

^c2 x 10⁷ BALB BM cells into CC3F₁, (900 rad).

^dValues represent percentage of BALB donor cells in CC3F₁ recipients as determined by the Gpi assay. Each value represents analyses as performed on 10 animals.

Table 13

Attempts to Produce Fully Allogeneic Antibody-Facilitated Chimeras with Bone Marrow Cells and anti-H-2K^b Monoclonal Antibody.

CELL SOURCE ¹	mAb ²	RECIPIENT ³	N	%DONOR CELLS ⁴
2 x 10 ⁷ BMC	aK ^b	CC3F ₁	10	>95
2 x 10 ⁷ BMC	None	CC3F ₁ (900R)	5	>95
2 x 10 ⁷ BMC	None	C3H(900R)	5	>95
2 x 10 ⁷ BMC	aK ^b	C3H	5	0
6 x 10 ⁷ BMC	aK ^b	C3H	5	0
10 ⁸ SC + 2 x 10 ⁷ BMC	aK ^b	C3H	5	0

¹BALB spleen cells (SC) or bone marrow cells (BMC).

²416 µg of anti-H-2K^b (aK^b) (11-4.1) monoclonal antibody.

³CC3F₁ = (BALB/cCR x C3H/HeJ)F₁.

⁴Percentage of BALB donor cells in CC3F₁, host peripheral blood as determined by the glucose phosphate isomerase assay. Determinations were made 8 weeks postinjection.

Table 14

Attempts to Produce Completely Allogeneic Antibody-Facilitated Chimeras. (BALB/cCR $\rightarrow$ C3H/HeJ).

TREATMENT		RECIPIENT	% OF DONOR CELLS/WEEK ³		
$\alpha\theta$ BM ¹	mAb ²		6	8	12
4 x 10 ⁷	.6ml α K ^k	C3H	0	0	0
4 x 10 ⁷	.45ml α K ^k	C3H	0	0	0
4 x 10 ⁷	.3ml α K ^k	C3H	0	0	0
4 x 10 ⁷	900 rad	C3H	>95	>95	>95

¹BALB bone marrow cells treated with anti-thy-1.2 + complement.

²anti-H-2K^k (α K^k) (11-4.1) monoclonal antibody.

³Percentage of BALB donor cells in C3H host peripheral blood as determined by the glucose phosphate isomerase assay. Each value represents the mean (standard deviation) of 10 mice per group.

fully allogeneic barriers. 8×10^7 BALB α BM cells, along with both anti-H-2K^b and anti-H-2I-A^b mAbs, did not produce any detectable level of chimerism (Table 15).

E. Health Status of Antibody-Facilitated Chimeras

Thus far, stable AF chimeras have been maintained in good health for long periods (> 2 years) without mortality. In no instance have any of the AF chimeras exhibited overt clinical signs of GVHD, such as weight loss, diarrhea, skin lesions, or ruffled or dull fur. The histopathologic status of two groups of long-term AF chimeras was evaluated. Group 1 (BALB x C3H)F₁ received 2.5×10^7 BALB BM cells plus anti-H-2K^b mAb, and were examined > 90 days later. Group 2 (DBA x C3H)F₁ received 10^8 spleen cells and 2.5×10^7 BM cells from DBA donors plus anti-H-2K^b mAb and were examined more than a year later. Both of these AF chimeric groups were compared with normal, age-matched controls. All groups consisted of five mice.

No pathological changes associated with acute or chronic GVHD were discernible in AF chimeras that were produced with mAb and untreated BM cells alone (Group 1). Recipients' kidneys did not show signs of chronic, progressive glomerulonephritis, the hallmark of GVHD (Plate 1). In addition, the liver (Plate 2) and lungs (Plate 3) appeared quite normal.

In contrast to group 1, group 2 mice exhibited some evidence of localized tissue injury, particularly to the

Table 15

Attempts to Produce Fully Allogeneic AF Chimeras with Bone Marrow Cells and Anti-H-2K^k and Anti-H-2I-A^k mAbs.

CELL SOURCE ¹	mAb ²	RECIPIENT ³	%DONOR CELLS ⁴
2 x 10 ⁷ BMC	α K ^k	CC3F ₁	>95
4 x 10 ⁷ BMC	α I-A ^k	CC3F ₁	>95
4 x 10 ⁷ BMC	α I-A ^k	C3H/HeJ	0
8 x 10 ⁷ BMC	α I-A ^k	C3H/HeJ	0
4 x 10 ⁷ BMC	α K ^k + α I-A ^k	C3H/HeJ	0
8 x 10 ⁷ BMC	α K ^k + α I-A ^k	C3H/HeJ	0
2 x 10 ⁷ BMC	None	C3H/HeJ (900 rad)	>95

¹BMC - BALB bone marrow cells.

² α K^k - anti-H-2K^k (11-4.1) monoclonal antibody; α I-A^k - anti-H-2I-A^k (10-3.6) monoclonal antibody

³CC3F₁ - (BALB/cCR x C3H/HeJ)F₁

⁴Percentage of BALB/cCR donor cells in CC3F₁ and C3H/HeJ host peripheral blood as determined by the glucose phosphate isomerase assay, determinations made 8 weeks post-injection. Each value represents the mean (standard deviation) of 10 mice per group.




Plate 1. Photomicrograph of kidney from long-term AF chimera. Tissue structure appears normal, no evidence of GVHD (H&E X200).




Plate 2. Photomicrograph of liver from long-term AF chimera. Tissue structure appears normal, no evidence of GVHD (H&E X200).




Plate 3. Photomicrograph of lung from long-term AF chimera. Tissue structure appears normal, no evidence of GVHD (H&E X200).

lymphoid tissue. The lymph nodes and thymii were markedly atrophied and could not be clearly defined. The spleens were smaller than those of control mice and, in some instances, nodular. The spleen cell count ($87 \pm 40 \times 10^6$) was approximately one-half that of controls ($179 \pm 14 \times 10^6$). The most striking feature was granulomatus panniculitis leading to the pronounced thickening of the subcutis. In contrast, the kidney (Plate 4), liver (Plate 5), and lung (Plate 6) appeared normal except for occasional lymphocytic infiltrations around vessels. This infiltration was also seen in the mice which received bone marrow cells and mAb but to a lesser extent.




Plate 4. Photomicrograph of section of kidney from a Group 2, anti-H-2K^b AF Chimera. Some evidence of lymphocyte infiltration is seen (H&E X200).




Plate 5. Photomicrograph of section of liver from a Group 2, anti-H-2K^b AF Chimera. Some evidence of lymphocyte infiltration is seen (H&E X200).




Plate 6. Photomicrograph of section of lung from a Group 2, anti-H-2K^b AF Chimera. Some evidence of lymphocyte infiltration is seen (H&E X200).

Discussion

Antibody-facilitated (AF) chimeras demonstrate that the administration of anti-MHC mAbs can give rise to the engraftment and subsequent generation of donor-type hemopoietic cells in a host environment. These chimeras are established by repopulating F₁ hybrid recipients with parental hemopoietic cells derived from bone marrow or spleen, or both, in conjunction with an IgG2a mAb directed against host Class I or Class II MHC antigens. Under appropriate conditions, this can lead to complete host hemopoietic takeover by donor cells in a semiallogeneic model [DBA $\rightarrow$ (DBA $\times$ C3H)F₁, or BALB $\rightarrow$ (BALB $\times$ C3H)F₁] (Francescutti *et al.*, 1983). Electrophoretic analysis of Gpi isozymes indicates that once takeover has been established, usually by 8 to 10 weeks, it is stable and persists for more than 24 months post-transplantation without any signs of GVHD.

The role of the mAb isotype, IgG2a (complement binding), that is used in the AF chimera model is of importance and warrants further discussion. Carlson (Carlson and Terres, 1976; personal communication) have shown that this particular subclass of immunoglobulin has marked *in vivo* effects as compared to other immunoglobulin subclasses tested. Recently, Wegmann (data not shown) has found that he was unable to facilitated hemopoietic engraftment in a P $\rightarrow$ F₁ model if he used an antibody of IgG1 (non-complement binding) subclass. These findings suggest that complement

may possibly be involved in the establishment of a successful marrow transplant.

Initially, AF chimeras were prepared utilizing the spleen as a source of stem cells. In an attempt to reduce our donor cell inoculum, we decided to use bone marrow instead. BM cell dose-response studies suggested that a threshold number of donor cells is required to achieve engraftment and another, larger, threshold number is required for complete takeover. It is interesting to note, that the donor cellular requirements for engraftment using the anti-Class II, anti-H-2I-A^k, mAb are double that needed if the mAb was instead directed against Class I MHC target antigens. This finding may be related to the role that the various mAbs play in their preparation of the host prior to engraftment. The anti-Class I mAb may simply be more effective in providing "space" for donor stem cells to differentiate in, whereas the kinetics in the case of anti-Class II reconstitution necessitates an increase in the number of donor stem cells required. The donor cell inoculum used as a source of stem cells can be derived from anti-Thy-1.2-treated or untreated BM cells. MAbs directed against both Class I or Class II MHC antigens are able to facilitate hemopoietic reconstitution of the recipients by donor stem cells.

Waldor *et al.*, 1984 have shown that the injection of anti-I-A monoclonal antibody (anti-H-2I-A^k(10-3.6)) into SJL/J mice rapidly depletes B cell levels. They noted that

one day after the mice were treated with the mAb, a significant drop in splenic IgM positive, IgD positive B cells was observed. Recovery to relatively normal levels of B cells took approximately 33 days. These values correlate with the transient drop in the buffy coat values that we found in the treatment of our chimeras.

The *in vitro* treatment by anti-Class II mAb may be causing the destruction of committed progenitors which have been shown to bear appropriate Class II antigens while lacking an effect on pluripotential stem cells. *In vitro* hemopoiesis is not dependent on viable Ia positive cells. In contrast, *in vivo* treatment by anti-Class II mAb may be inducing aplasia by the killing of committed stem cells and/or by possibly having an effect on monocytes, IL-1 or GM-CSF production? The ability to induce immune suppression in the hosts by these mAb's has never been addressed directly. Although one can envisage that this induction of immunosuppression may actually be occurring in the $P \rightarrow F$ model, in contrast to the $P_1 \rightarrow P_2$ model where resistance to immunosuppression has prevented us from achieving any degree of chimerism.

Class I molecules are thought to be present on almost all somatic cells, albeit at varying concentrations (O'Neill, 1984; Parr and Kirby, 1979; Daar *et al.*, 1984). However, Class II molecules are characteristic of cells of the immune system but not necessarily of all hemopoietic progenitor cells, although these determinants may be

expressed on bone marrow stromal cells (Moore *et al.*, 1980; Fitchen *et al.*, 1981). These stromal cells are thought to be intimately involved in the self-renewal and differentiation of stem cells (Dexter, 1982a). Reticular or related, branched stromal cells, in addition to macrophages and lymphocytes, are closely involved with the maintenance of hemopoietic activity (Weiss, 1980). Van Ewijk (1980), has shown that these accessory or supportive cells bear both Class I and Class II MHC antigens.

Our findings that the anti-Class I mAb (anti-H-2K^b) was able to significantly reduce the numbers of CFU-S in appropriate target mice are in agreement with those of Fitchen *et al.*, 1982. In addition they went on to show that the anti-H-2K^b mAb also inhibited the development of myeloid (CFU-C) and erythroid (CFU-E) stem cells as well. They used fresh frozen normal rabbit serum as a source of complement in the treatment of the marrow. They also reported that the addition of thymocytes to the marrow cells, after they had been antibody treated, did not overcome the inhibitory effects of the antibody treatment.

CFU-S are inhibited by anti-H-2K^b mAb pretreatment *in vitro* but not by anti-H-2I-A^b mAb pretreatment. The *in vivo* administration of anti-H-2K^b or anti-H-2I-A^b mAbs results in a marked decrease in the CFU-S capacity of relevant C3H and (BALB x C3H)F₁ bone marrow. Therefore, it is likely that the action of anti-Class II mAb *in vivo* is to interfere with the maintenance of hemopoiesis, while anti-Class I mAb *in vivo*

possibly affects stem cells and/or regulatory cells. Taken together, these observations suggest that interference with host regulatory cells can lead to the elimination of host stem cells and the replacement of the hemopoietic system by donor cells. The action of our anti-host MHC mAbs may facilitate donor engraftment by suppressing host resistance to marrow grafts, as described by Cudkowicz (1978) for rabbit anti-mouse bone marrow or thymocyte serum, and by Pollack and colleagues in which they successfully prevented the rejection of allogeneic bone marrow transplants by the *in vivo* pretreatment of the host with an antiserum specific against the NK-cell surface antigen NK 1.1 (Pollack et al., 1979).

Other aspects of these AF chimera studies further implicate the important regulatory role of the local cellular microenvironment for stem cell growth. Our dose-response studies indicate that the conditions favoring donor cell repopulation depend on the number of infused cells and on the type of mAb treatment. The establishment and the extent of donor cell engraftment probably reflects the availability of stem cell niches and competition between donor and host hemopoietic cells for such sites, a concept introduced by Schofield (1978). Success in establishing semiallogeneic AF chimeras and the inability to facilitate engraftment in the fully allogeneic model reflects the necessity for compatibility between donor cells and the host microenvironment. Possibly, this reflects inadequate

immunosuppression by mAb of the fully allogeneic recipient particularly in view of the demonstration by Dexter (1977c, 1978) that long-term bone marrow cultures do not require histocompatible adherent cell layers.

It is of interest to note that donor cells and antihost mAb do not need to be injected simultaneously to produce AF chimeras. We found that cells could be administered either 2 or 5 days prior to the mAb (day 0) or the mAb may be given 5 or 7 days prior to the cells. This suggests that the donor cells can be successfully maintained in the untreated recipient prior to the administration of the mAb at day 0. Likewise, the effects of the mAb on the host remain stable over a short period of time in that a subsequent injection of stem cells 5 or 7 days post mAb treatment still permits donor takeover of the recipient to occur. Bone marrow or spleen stem cell colonies grown in methyl cellulose cultures were examined to determine if any host hemopoietic precursor cells were still present in fully (>95%) or partially (<95%) repopulated AF chimeras. It was felt that this *in vitro* assay would allow the detection of host precursor cells, even if an *in vivo* regulatory control prevented their differentiation. The sensitivity of the Gpi assay is such that colonies as small as a few hundred cells can be quickly and accurately phenotyped. We found that close correlations exist between the degree of donor colonies derived from either spleen or bone marrow and the level of donor cells in the peripheral blood (Francescutti *et al.*, in press, 1985).

These findings are of particular interest in view of the fact that residual host cell population among differentiated cells of the spleen, thymus and lymph nodes are of substantial size in AF chimeras that have complete donor engraftment of peripheral blood, bone marrow and spleen stem cell compartments (McCarthy *et al.*, 1985). This demonstrates that although the hemopoietic stem cell compartment of the spleen is comparable to that of the bone marrow and is reflected in the red and white cells of the peripheral blood, an independent population of long-lived host cells remains in secondary lymphoid organs. McCarthy speculates that this could possibly be due to the differential expression of target antigens on leukocytes recognized by the mAb's; also, residual cells may be long-lived memory cells that have somehow escaped the effects of the mAb treatment. Alternatively, the microanatomical location within the organs in question may protect the host cells from antibody. These possibilities are the subject of current investigations in Wegmann's laboratory.

Conflicting reports exist as to whether the marrow stroma is a transplantable element. Keating *et al.* (1982) have shown that the hemopoietic microenvironment following marrow transplantation in man is of donor origin. In contrast Bentley (1982) could not find chromosomally-marked donor cells in long-term cultured adherent cell layers derived from the bone marrow of repopulated irradiated mice. Dexter (1982b) notes that the two models differ in that

cyclophosphamide was used in addition to the irradiation treatment in the human study. He postulates that cyclophosphamide possibly creates "space" in the hemopoietic tissue, thereby allowing donor stromal cell precursors an opportunity to establish themselves. The mAb treatment used in establishing the AF chimeras may be acting in a similar fashion. Examination of the stem-cell enriched non-adherent layer arising from long-term bone marrow cultures indicates that it is at least 95% donor derived. On the other hand, the microenvironment-associated adherent layer, which consists of macrophage-like, fibroblastoid, epithelioid and fat-containing cells, is only 72 - 77% donor origin. The host cells in this particular population may be an outgrowth of fibroblast cells from the original bone marrow plug used to inoculate the cultures, a finding similar to that reported by Freidenstein *et al.* (1978) and Golde *et al.* (1980) in their respective studies. Gpi analysis of the AF chimera bone marrow plug prior to the long-term bone marrow culture indicates that the cells are >95% of donor origin. A minority (<5%) host cell population with the potential to repopulate as much as 25% of the adherent layer in long-term bone marrow cultures therefore seems to persist in AF chimeras. The functional significance of this cell population remains to be determined. The findings with the AF chimeras are similar to those of Marshall *et al.*, (1984) who report that reciprocal bone marrow transplantation between irradiated CBA/H(T6) Gpi congenics yields a similar

70 or so percent takeover of the adherent layer of long-term bone marrow cultures by donor cells.

It has been shown that peritoneal exudate macrophages originate from bone marrow stem cells (Thompson, 1970). The extent of donor takeover in peritoneal exudate macrophages was examined and found to be similar to the level of takeover in both the peripheral blood and marrow stem cell compartments, with a small amount of residual host cell contamination.

Hemopoietic analysis therefore shows that the amount of donor engraftment seen in the peripheral blood and peritoneal macrophages of the AF chimeras is a true reflection of the degree of hemopoietic stem cell reconstitution. These findings also indicate that once hemopoietic takeover by donor cells has occurred in AF chimeras, it is permanent and that the level of chimerism in the peripheral blood is an accurate indication of the hemopoietic stem cell mixture in both the bone marrow and the spleen.

The immunological competence of our AF chimeras has been tested thoroughly by Wegmann's group (McCarthy *et al.*, submitted). Immunocompetence of T and B lymphocytes was examined in both proliferative and effector cell assays. The AF chimeras showed normal responses to a variety of mitogenic and antigenic challenges, and were capable of mounting normal cell-mediated immune responses. In addition, splenic lymphocytes (P_1 cells in a $(P_1 \times P_2)F_1$ host) were

found to be hyporesponsive or nonresponsive to host antigens of parental donor haplotype in *in vitro* assays of cell-mediated immunity. As in the earlier parabiosis model, no direct *in vitro* evidence for active suppression of the anti-host cytotoxic response was found. Further, no detectable anti-P₂ antibodies could be found in the serum of the AF chimeras, as tested by both a CFU-S assay and a competitive radioimmunoassay.

AF chimeras are healthy mice that can survive for more than 24 months post-transplantation. Both male and female AF chimeras demonstrate normal reproductive functions (Gambel *et al.*, 1985). Long-term AF chimeras, when compared to normal controls, do not show any increased incidence of malignancies. When BM is used as a source of donor cells, there is no clinical evidence of any tissue injury characteristic of acute or chronic GVHD. When spleen and BM cells are used in the donor inoculum, the histopathologic picture of these long-term AF chimeras (> 1 year) indicates some minimal signs of chronic but nonlethal GVHD. In particular, there is no evidence for glomerulonephritis or advanced scleroderma. However, atrophy of lymphoid tissue and granulomatous panniculitis is quite evident. This destruction of lymphoid tissue leads to generalized immunosuppression. The thickening of the subcutis has been associated with a phase of repair in chronic GVHD, as described by Elkins (1971).

Two requirements for induction of the symptoms of chronic GVHD are the presence of immunocompetent T cells in the donor inoculum and the ability of these cells to react to an incompatible recipient (Rappaport, 1979). However, GVHD-inducing capacities of different mouse strains vary. The poor capability of DBA cells to induce lethal GVHD has been described for parabionts and radiation chimeras (Drell *et al.*, 1979b; Van Elven *et al.*, 1981). BALB mice, however, differ from their DBA counterparts in their stronger ability to induce GVHD.

In summary, these findings demonstrate an important new concept in the production of hemopoietic chimeras: immunosuppressive agents and irradiation are not always necessary for a successful hemopoietic engraftment, at least in the particular strain combinations that we have tested to date. We hope these studies will play a role in the search for a new and better means of performing clinical bone marrow transplantation appropriate for certain hematologic disorders.

Future Directions

Bone marrow transplantation has the potential of becoming a cornerstone modality of therapy for a great variety of hemopoietic and genetically inherited disorders. One only has to imagine the spectrum of genetic disorders that hold promise of being amendable to genetic engineering. As mentioned in the introduction, the defects in the thalassemias, the hemoglobinopathies, the anemias, Lesch-Nyhan disease, purine nucleoside phosphorylase deficiency leading to a severe immunodeficiency disease, and adenosine deaminase deficiency which causes a severe combined immunodeficiency disease (Sondel *et al.*, 1983; Anderson, 1984), can all theoretically be repaired via sophisticated gene therapy (Good *et al.*, 1984). There are currently four broad groups of techniques for transferring cloned genes into cells. First, there is the use of viruses as agents of gene delivery. These can be either DNA or RNA viruses (retroviruses) (Joyner *et al.*, 1983; Risser *et al.*, 1983). Secondly, Wigler *et al.*, (1977) describe a modified version of calcium phosphate-mediated DNA uptake originally reported by Graham and van der Eb (1973). A third means is by the fusion of DNA-loaded membranous vesicles to cells (Anderson, 1984). Finally, physical means, such as microinjection (Anderson *et al.*, 1980a) and electroporation, or the transfer of DNA directly across the cell membrane using an electric current (Neumann *et al.*, 1982), can be exploited. Experiments in various animal models strongly

suggest that gene insertion can successfully be done (Hammer *et al.*, 1984; Mercola *et al.*, 1980a, 1980b; Skow *et al.*, 1983; Cline *et al.*, 1980; Miller *et al.*, 1984; Williams *et al.*, 1984).

Proper host preparation will consist primarily of the removal of the defective cell populations in a selective fashion, ensuring that the supportive structural stromal environment is not destroyed and, finally, successfully reintroducing the corrected stem cell population back into the recipient. A common factor in these requirements is the specificity of cell destruction and replacement. Specificity is stressed, since present modalities of host preparation and selective cell removal are nonspecific, including the use of total body irradiation and various cytotoxic drugs, such as alkylating agents. These agents have been implicated in a variety of unwanted side effects, including the increased incidence of subsequent malignancy and the possibility of permanent damage to hemopoietic tissue.

The specificity inherent in our AF chimera model is a major step towards eliminating these undesirable side effects. One can envisage extensions of our protocol, for instance, utilizing a wider spectrum or combination of mAbs with varying specificities directed at unique target antigens. These targets may involve abnormal hemopoietic cells, leukemic cells, or any cell population bearing appropriate markers. This method of selective removal would create "space" in a manner likely to encourage subsequent

engraftment by the corrected stem cells. As indicated by our time frame studies, it may be feasible to create a "window effect", thus allowing us a certain time frame in which we could control the hemopoietic reconstitution of the hosts.

Anderson (1980b; 1984) thoroughly reviews the prospects for human gene therapy in a recent article. He states quite emphatically and logically that "...it should be shown in animal studies that (i) the new gene can be put into the correct target cells and will remain there long enough to be effective; (ii) the new gene will be expressed in the cell at appropriate levels and (iii) the new gene will not harm the cell or, by extension, the animal."

Syngeneic studies with these goals in mind are the subject of current investigations by Wegmann's group.

Bibliography

- Allalunis MJ, Chapman JD, Turner AR. Identification of a hypoxic population of bone marrow cells. *Int J Radiation Oncology Biol Phys* 1983; 9: 227.
- Anderson WF, Killos L, Sanders-Haigh L, Kretschmer PJ, Diacumakos EG. Replication and expression of thymidine kinase and human globin genes microinjected into mouse fibroblasts. *Proc Nat Acad Sci - USA* 1980a; 77: 5399.
- Anderson WF, Fletcher JC. Gene therapy in human beings: when is it ethical to begin ? *Nature* 1980b; 303: 1293.
- Anderson WF. Prospects for human gene therapy. *Science* 1984; 226: 401.
- Applebaum FR, Storb R, Ramberg RE, Shulman HM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Allogeneic marrow transplantation in the treatment of preleukemia. *Ann Intern Med* 1984; 100: 689.
- Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Cyclosporin-associated central nervous system toxicity after allogeneic bone marrow transplantation. *Transplantation* 1984; 38: 34.
- August CS, Rosen FS, Filler RM, Janeway CA, Markowski B, Kay HEM. Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (DiGeorge's syndrome). *Lancet* 1968; 2: 1210.
- Barnes DWH, Louitt JF. in "Radiobiology Symposium Liege" ed. Bacq ZM. *Butterworths* London 1956: p 134.
- Batchelor JF, Howard JG. Synergic and antagonistic effects of isoantibody on graft-versus-host disease. *Transplantation* 1965; 3: 161.
- Beck WS. In: Hematology. MIT Press. Cambridge. 1982: p 37.
- Bentley SA, Knutsen T, Whang-Peng J. The origin of the hematopoietic microenvironment in continuous bone marrow cultures. *Exp Hematol* 1982; 10: 367.
- Bennett JA, Rao VS, Mitchell MS. Systemic Bacillus Calmette-Guerin (BCG) activates natural suppressor cells. *Proc Nat Acad Sci, USA* 1978; 75: 5142.
- Bennett JA, Mitchell MS. Systemic administration of BCG

activates natural suppressor cells in the bone marrow and stimulates their migration into the spleen. In: *Neoplasm and Immunity: Experimental and Clinical*. ed. Crispen RG. Amsterdam: Elsevier/North Holland 1980: p 397.

Beschorner WE, Tutschka PJ, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. *Transplantation* 1982; 33: 393.

Bevan MJ. In a radiation chimera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells. *Nature* 1977; 269: 417.

Biggar WD, Park BH, Good RA. Immunologic reconstitution. *Ann Rev Med* 1973; 24: 135.

Blume KG for the City of Hope Bone Marrow Transplantation Group. Early bone marrow transplantation in acute leukemia. *Blut* 1980; 41: 405.

Boggs DR and Boggs SS. The effect of graded, single doses of busulfan on murine erythropoiesis. *Proc Soc Exp Biol Med* 1980; 163: 181.

Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. *Nature* 1979; 5731: 490.

Bortin MM, Truitt RL, Shih CY, Rimm AA. Graft-versus-leukemia: Allosensitization of MHC compatible donors induces antileukemic reactivity without amplification of antihost reactivity. *Haematol Bluttransfus* 1981; 25: 31.

Bortin MM, Gale RP, Kay HEM, Rimm AA. Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukemia. *Lancet* 1982; 8269: 437.

Botnick LE, Hannon EC, Hellman S. Multisystem stem cell failure after apparent recovery from alkylating agents. *Cancer Research* 1978; 38: 1942.

Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. *Aust J Exp Biol Med Sci* 1966; 44: 287.

Brown III CH, Carbone PR. Effects of chemotherapeutic agents on normal mouse bone marrow grown *in vitro*. *Cancer Res* 1971; 31:185.

Buckner CD, Briggs R, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE, Storb R, Thomas ED. Intermittent high dose

cyclophosphamide (MSC-26271) treatment of stage III ovarian carcinoma. *Cancer Chemotherapy Rept* 1974; 58: 697.

Buckner CD, Clift RA, Thomas ED, Hersman J, Sanders JE, Stewart PS, Wade JC, Murphy M, CCounts G, Meyers JD. Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: effects of prophylactic measures. *Infection* 1984; 11: 243.

Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rapoport JM, Santos G, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. *Blood* 1979; 53: 504.

Cantrell JL, Hildemann WH. Characteristics of disparate histocompatibility barriers in congenic strains of mice. *Transplantation* 1972; 14: 761.

Carlson G, Terres G. Antibody-induced killing *in vivo* of L1210/MTX-R cells quantitated in passively immunized mice with ^{125} I-iododeoxyuridine labelled cells and whole-body measurement of retained radioactivity. *J Immunol* 1976; 117: 822.

Carlson G, Wegmann TG. Rapid *in vivo* destruction of semi-syngeneic and allogeneic cells by nonimmunized mice as a consequence of nonidentity at H-2. *J Immunol* 1977; 118: 2130.

Cleveland WW, Fogel BJ, Brown WT, Kay HEM. Foetal thymic transplant in a case of DiGeorge's syndrome. *Lancet* 1968; 2: 1211.

Cline MJ, Stang H, Mercola KE, Morse L, Ruprecht R, Browne J, Salser W. Gene transfer in intact animals. *Nature* 1980; 284: 422.

Cudkovicz G, Stimpfling JH. Deficient growth of C57Bl mouse marrow cells transplanted in F₁ hybrid mice. Association with the histocompatibility-2 locus. *Immunology* 1964; 7: 291.

Cudkovicz G, Landy M, Shearer GM. Natural resistance systems against foreign cells, tumors and microbes. New York: Academic Press. 1978.

Daley JP, Nakamura I. Natural resistance of lethally irradiated F₁ hybrid mice to parental marrow grafts is a function of H-2/HH-restricted effectors. *J Exp Med* 1984; 159: 1132.

Darr AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The

- detailed distribution of HLA-A, B, C antigens in normal human organs. *Transplantation* 1984; 38: 287.
- Deeg HJ, HJ, Storb R, Prentice R, Fritz TE, Weiden PL, Sale GE, Graham TC, Thomas ED. Increased cancer risk in canine radiation chimeras. *Blood* 1980; 55: 233.
- Deeg HJ, Prentice R, Fritz TE, Sale GE, Lombard LS, Thomas ED, Storb R. Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation. *Int J Radiat Oncol Biol Phys* 1983; 9: 1505.
- Deeg HJ, Storb R, Thomas ED. Bone marrow transplantation: A review of delayed complications. *Brit J Haematol* 1984a; 57: 185.
- Deeg HJ, Storb R, Appelbaum FR, Kennedy MS, Graham TC, Thomas ED. Combined immunosuppression with Cyclosporin and Methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. *Transplantation* 1984b; 37: 62.
- Dexter TM, Allen TD, Lajtha LG, Schofield R, Lord BI. Stimulation of differentiation and proliferation of haemopoietic cells in vitro. *J Cell Physiol* 1973; 82: 461.
- Dexter TM, Moore MAS. In vitro duplication and 'cure' of haemopoietic defects in genetically anemic mice. *Nature* 1977a; 269: 412.
- Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. *J Cell Physiol* 1977b; 91: 335.
- Dexter TM, Moore MAS, Sheridan APC. Maintenance of hemopoietic stem cells and production of differentiated progeny in allogeneic and semiallogeneic bone marrow chimeras *in vitro*. *J Exp Med* 1977c; 145: 1612.
- Dexter TM, Spooncer E. Loss of immunoreactivity in long-term bone marrow culture. *Nature* 1978; 275: 135.
- Dexter TM. Is the marrow stroma transplantable? *Nature* 1982b; 298: 222.
- Dexter TM. Stromal cell associated hemopoiesis. *J Cell Physiol (Suppl)* 1982a; 1: 87.
- Dorshkind K, Phillips RA. Characterization of early B lymphocyte precursors present in long-term bone marrow cultures. *J Immunol* 1983; 131: 2240.

- Drell DW, Carlson GA, Wegmann TG. Presence of circulating anti-H-2 antibody and cell-mediated precursors in successful DBA/2J $\rightarrow$ (DBA/2J x C3H/HeJ)F₁ parabiosed mice. *J Immunol* 1979a; 123: 2319.
- Drell DW, Wegmann TG. Immunological and genetic requirements for the parental hemopoietic takeover reaction in adult, H-2 incompatible parent $\rightarrow$ F₁ hybrid parabiosis. *Immunogenetics* 1979b; 8: 221.
- Drell DW, Carlson GA, Wegmann TG. Long-term persistence of non-tolerant cells after adult H-2-incompatible parabiosis. *Transplant Proc* 1979; XI: 1448.
- Drizlikh G, Schmidt-Sole J, Yankelevich B. Involvement of the K and I regions of the H-2 complex in resistance to hemopoietic allografts. *J Exp Med* 1984; 159: 1070.
- Elkins WL. Cellular immunology and the pathogenesis of graft-versus-host reactions. *Prog Allergy* 1971; 15: 78.
- Fausser AA, Messner HA. Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neutrophilic granulocytes and erythroblasts. *Blood* 1979; 53: 1023.
- Filipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kesey JH. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. *Lancet* 1982; 8284: 1266.
- Fitch JH, Foon KA, Cline MJ. The antigenic characteristics of hematopoietic stem cells. *N Eng J Med* 1981; 305: 17.
- Fitch JH, Hays EF, Ferrone S. Expression of the H-2 antigenic complex on murine haematopoietic stem cells. *Scand J Immunol* 1982; 15: 547.
- Forman SJ, Farbstein MJ, Scott EP, Wolf JL, Spruce WE, Fahey JL, Nademanee A, Blume KG. Prevention and therapy of graft-versus-host disease. *N Engl J Med* 1982; 307: 376.
- Fox M. Cytological estimation of the proportion of proliferating donor cells during graft-versus-host disease in F₁ hybrid mice injected with parental spleen cells. *Nature* 1962; 195: 1024.
- Francescutti LH, Gambel P, Wegmann TG. Injection Chimeras: A model for the production of complete hemopoietic takeover in histoincompatible adults. *Transplant Proc* 1983; 15: 1477.
- Francescutti LH, Gambel P, Wegmann TG. Characterization of

hemopoietic stem cell chimerism in antibody-facilitated chimeras. *Transplantation* 1985; in press.

Frasconi F, Testa NG, Lord BI. The relative spatial distribution of erythroid progenitor cells (BFU-E and CFU-E) in the normal mouse femur. *Cell Tissue Kinetics* 1982; 15: 447.

Fried W and Johnson C. The effect of cyclophosphamide on hematopoietic stem cells. *Rad Res* 1968; 36: 521.

Fried W, Kedo A, Barone J. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. *Cancer Res* 1977; 37: 1205.

Friedenstein AJ, Ivanov-Smolenski AA, Chailakhjan RK, Gorskaya VF, Kuralesova AI, Latzinik NW, Gerasimow VW. Origin of bone marrow stromal melanocytes in radiochimeras and heterotopic transplants. *Exp Hematol* 1978; 6: 440.

Gale RP. Progress in bone marrow transplantation in man. *Surv Immunol Res* 1982; 1: 40.

Gambel P, Francescutti LH, Wegmann TG. Antibody-Facilitated Chimeras: Stem cell allotransplantation using antihost major histocompatibility complex monoclonal antibodies instead of lethal irradiation for host conditioning. *Transplantation* 1984; 38: 152.

Gambel P, Rossant J, Hunziker RD, Wegmann TG. Decidual cells in murine pregnancy and pseudopregnancy: origin and natural killer cell activity. *Transplant Proc* 1985; XVII: 905.

Gatti RA, Allen HD, Meuwissen HJ, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet* 1968; 2: 1366.

Gatti RA, Good RA. Follow-up of correction of severe dual system immunodeficiency with bone marrow transplantation. *J Pediatr* 1971a; 79: 475.

Gatti RA, Meuwissen JH, Terasaki PI, Good RA. Recombination within the HLA locus. *Tissue Antigens* 1971b; 1: 239.

Gleichmann E, Gleichmann H, Wilke W. Autoimmunization and lymphomagenesis in Parent $\rightarrow$ F₁ combinations differing at the major histocompatibility complex: Model for spontaneous disease caused by altered self-antigens. *Transplant Rev* 1976; 31: 156.

Gleichmann E, Van Elven EH, Van der Veen JPW. A systemic lupus erythematosus (SLE)-like disease in mice induced

- by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. *Eur J Immunol* 1982; 12: 152.
- Gleichmann E, Pals ST, Rolnick AG, Radaszkiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. *Immunology Today* 1984; 11: 324.
- Gluckman E, Barrett J, Arcese W, Devergie A, Degoulet P. Bone marrow transplantation in severe aplastic anemia - A survey of the European Group for Bone Marrow Transplantation. *Br J Haematol* 1981; 49: 165.
- Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA- matched sibling donors. *Transplantation* 1974; 18: 295.
- Golde DW, Hocking WG, Quan SG, Sparkes RS, Gale RP. Origin of human bone marrow fibroblasts. *Br J Haemat* 1980; 44: 183.
- Good RA, Kapoor N, Reisner Y. Bone marrow transplantation - an expanding approach to treatment of many diseases. *Cellular Immunology* 1983; 82: 36.
- Good RA, Kapoor N, Day NK, Reisner Y. Cellular engineering through marrow transplantation. *Prog Clin Biol Res* 1984; 149: 271.
- Goodman JW, Shinpock SG. Influences of thymus cells on erythropoiesis of parental marrow in irradiated hybrid mice. *Proc Soc Exp Biol Med* 1968; 129: 417.
- Goodman JW, Shinpock SG. Further studies on the relationship of the thymus to haemopoiesis. *Transplantation* 1972; 13: 203.
- Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 1973; 52: 456.
- Graze PR, Gale RP. Chronic graft-versus-host disease: A syndrome of disordered immunity. *Am J Med* 1979; 66: 611.
- Grebe SC, Streilein JW. Graft-versus-host reactions: A review. *Adv Immunol* 1976; 22: 119.
- Greenberger JS. Sensitivity of corticosteroid dependent insulin-resistant lipogenesis in marrow preadipocytes of obese-diabetic (db/db) mice. *Nature* 1978; 275: 752.

- Greenwood F, Hunter W, Glover J. The preparation of ^{125} I-human growth hormone of high specific radioactivity. *Biochem J* 1963; 89: 114.
- Halle-Panneko O, Pritchard LL, Mathe G. In: Recent Trends in the Immunology of Bone Marrow Transplantation. Thierfelder S (ed). *Blut* 1980: Sup 25.
- Hammer RE, Palmiter RD, Brinster RL. Partial correction of murine hereditary growth disorder by germ-line incorporation of a new gene. *Nature* 1984; 311: 65.
- Hansen JA, Woodruff JM, Good RA. The graft-vs-host reaction in man. Genetics, clinical features, and immunopathology. In: Comprehensive Immunology. Plenum Press 1981; 7: 229.
- Hansson M, Beran M, Andersson B, Kiessling R. Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. *J Immunol* 1982; 129: 126.
- Harper JI, Kendra JR, Desai S, Staughton RC, Barrett AJ, Hobbs JR. Dermatological aspects of the use of cyclosporin-A for prophylaxis of graft-versus-host disease. *Br J Dermatol* 1984; 110: 469.
- Hays EF, Hale L, Villarreal B, Fitchen JH. Stromal and hemopoietic stem cell abnormalities in long-term cultures of marrow from busulfan-treated mice. *Exp Hematol* 1982; 10: 383.
- Hellman S, Botnick LE, Hannon EC, Vigneulle RM. Proliferative capacity of murine hemopoietic stem cells. *Proc Nat Acad Sci USA* 1978; 75: 490.
- Hendry JH, Lord BI. The analysis of the early and late response to cytotoxic insults in the haemopoietic cell hierarchy. In: Cytotoxic insult to tissues: effects on cell lineages. Potten CS and Hendry JH (eds). *Churchill Livingstone* Edinburgh 1982; ch 1, p 1.
- Hodgson GS, Bradley TR, Martin RF, Sumner M, Fry P. Recovery of proliferating haemopoietic progenitor cells after killing by hydroxyurea. *Cell Tissue Kinet* 1975; 8: 51.
- Hodgson GS, Bradley TR, Radley JM. The organization of hemopoietic tissue as inferred from the effects of 5-fluorouracil. *Exp Hematol* 1982; 10: 26.
- Hobbs JR. The scope of allogeneic bone marrow transplantation. in *Advanced Medicine* Leeds by Losowsky MS, Bolton RP. *Pitman/Bath* 1983: p 378.
- Hong R, Kay HEM, Cooper MD, Meuwissen H, Allan MJG, Good RA.

Immunological restitution in lymphopenic immunological deficiency syndrome. *Lancet* 1968a; 1: 503.

Hong R, Gatti RA, Good RA. Hazards and potential benefits of blood-transfusion in immunological deficiency. *Lancet* 1968b; 2: 388.

Hows JM, Palmer S, Gordon-Smith EC. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. *Transplantation* 1982; 33: 382.

Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. *Nature* 1984; 5947: 168.

Iriondo A, Garijo J, Baro J, Conde E, Pastor JM, Saban'es A, Hermosa V, Sainz MC, P'erez de la Lastra L, Zubizarreta A. Complete recovery of hemopoiesis following bone marrow transplant in a patient with unresponsive congenital hypoplastic anemia (Blackfan-Diamond syndrome). *Blood* 1984; 64: 348.

Johnson GR, Metcalf D. Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin. *Proc Nat Acad Sci USA* 1977; 74: 3879.

Joyner A, Keller G, Phillips RA, Bernstein A. Retrovirus transfer of a bacterial gene into mouse haemopoietic progenitor cells. *Nature* 1983; 305: 556.

Kanojia MD, Anagnostou AA, Zander AR, Vellekoop L, Spitzer G, Verma DS, Jagannath S, Dicke KA. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. *Transplantation* 1984; 37: 246.

Kappler JW, Marrack P. The role of H-2 linked genes in helper T-cell function. IV. Importance of T-cell genotype and host environment in I-region and Ir gene expression. *J Exp Med* 1978; 148: 1510.

Keating A, Singer JW, Killen PD, Striker GE, Salo AC, Sanders J, Thomas ED, Thorning D, Fialkow P. Donor origin of the in vitro hematopoietic microenvironment after marrow transplantation in man. *Nature* 1982; 298: 280.

Keller G. Hemopoietic colonies on the chorioallantoic membrane of the chick embryo: Induction by embryonic, adherent, non hemopoietic spleen cells. *PhD Thesis* 1979. Univeristy of Alberta, Canada.

Kersey JH, Kim T, Levitt S, Krivit W, Nesbit ME, Coccia P, Warkentin P, O'Leary M, Ramsay NKC. Combined immunosuppression using cyclophosphamide plus total body irradiation in preparation for allogeneic marrow transplantation in humans. In: Immunobiology of bone marrow transplantation. Thierfelder S, Rodt J, Kolb HJ (eds). Springer-Verlag 1980: p 333.

Klein J. In: Immunology: The science of self-nonself discrimination. Wiley-Interscience. USA. 1982.

Korngold R, Sprent J. Lethal GVHD across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex. *Immunol Rev* 1983; 71: 5.

Longo DL, Matis LA, Schwartz RH. Insights into immune response gene function from experiments with chimeric animals. *CRC Crit Rev Immunol* 1981; 2: 83.

Longo DL, Davis ML. Early appearance of donor-type antigen-presenting cells in the thymus of 1200 r radiation-induced bone marrow chimeras correlates with self-recognition of donor I region gene products. *J Immunol* 1983; 130: 2525.

Lord BI, Hendry JH. The distribution of haemopoietic colony forming units in the mouse femur and its modification by x-rays. *Br J Radiology* 1972; 45: 110.

Lord BI, Schofield R. The influence of thymus cells in hemopoiesis: stimulation of hemopoietic stem cells in a syngeneic, in vivo, situation. *Blood* 1973; 42: 395.

Lord BI. Haemopoietic stem cells. In: Stem Cells Their Identification and Characterization. Potten CS (ed). Churchill Livingstone Edinburgh 1983: c 6, p 119.

Lotzová E, Cudkovicz G. Resistance of irradiated F₁ hybrid and allogeneic mice to bone marrow grafts of NZB donors. *Transplantation* 1973; 110: 791.

Lotzová E, Savary CA. Possible involvement of natural killer cells in bone marrow graft rejection. *Biomedicine* 1977; 27: 341.

Lotzová E, Gutterman JU. Effect of glucan on natural killer (NK) cells: further comparison between NK cells and bone marrow effector cell activities. *J Immunol* 1979; 123: 607.

Lotzová E. Analogy between rejection of hemopoietic transplants and natural killing. In: Natural cell-mediated immunity against tumors. Herberman RB

(ed). *Academic Press*; New York 1980: p 1117.

Lotzová E, Savary CA, Pollack SB. Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum. *Transplantation* 1983; 35: 490.

McCarthy SA, Francescutti LH, Gambel P, Griffith IJ, Semeluk A, Diener E, Wegmann TG. Identification of host lymphoid cells in antibody-facilitated bone-marrow chimeras. *Transplant Proc* 1985; XVII: 510.

Marshall MJ, Nisbet NW, Evans S. Donor origin of the *in vitro* hematopoietic microenvironment after marrow transplantation in mice. *Experientia* 1984; 40: 385.

Martin PJ, Hansen JA, Thomas ED. Preincubation of donor bone marrow cells with a combination of murine monoclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic bone marrow transplantation. *J Clin Immunol* 1984; 4: 18.

Mathe G, Jammet R, Pendic B, Schwarzenberg L, Duplan JF, Maupin B, Latarjet R, Larrieu MJ, Kalic D, Djukic Z. Transfusions and grafts of homologous bone marrow in humans after accidental high dosage irradiation. *Rev Fr Etude Clin Biol* 1959; 4: 226.

Mercola KE, Cline MJ. The potentials of inserting new genetic information. *N Eng J Med* 1980a; 303: 1297.

Mercola KE, Stang HD, Browne J, Salser W, Cline MJ. Insertion of a new gene of viral origin into bone marrow cells of mice. *Science* 1980b; 208: 1033.

Metcalf D. Hemopoietic colonies. In: *In vitro cloning of normal and leukaemic cells*. Springer Verlag Berlin 1977: p 227.

Metcalf D, Johnson GR. Production by spleen and lymph node cells of conditioned medium with erythroid and other hemopoietic colony-stimulating activity. *J Cell Physiol* 1978; 96: 31.

Metcalf D, Moore MAS. Haemopoietic cells. *North Holland Amsterdam* 1971: p 550.

Metcalf D, Johnson GR, Mandel T. Colony formation in agar by multipotential hemopoietic cells. *J Cell Physiol* 1979; 98: 401.

Meuwissen HJ, Gatti RA, Terasaki PI, Hong R, Good RA. Treatment of lymphopenic hypogammaglobulinemia and bone marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatibility matching. *N Engl J*

Med 1969; 281: 691.

Meyers JD, Thomas ED. Infection complicating bone-marrow transplantation. Chap 15, In: Clinical approach to infection in the immunocompromised host. Rubin RH, Young LS (eds). *Plenum Press*, New York 1982a: c 15, p 507.

Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience. *Rev Infect Dis* 1982b; 4: 1119.

Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snyderman DR, Wright GG, Levin MJ, Thomas ED. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. *Ann Intern Med* 1983; 98: 442.

Meyers JD. Cytomegalovirus infection following marrow transplantation: risk, treatment and prevention. *Birth Defects* 1984; 20: 101.

Micklem HS, Loutit JF. Tissue grafting and radiation. *Academic Press* New York 1966: p 1228.

Miller AD, Eckner RJ, Jolly DJ, Freidman T, Verma IM. Expression of a retrovirus encoding human HRPT in mice. *Science* 1984; 225: 630.

Moore MAS, Broxmeyer HE, Sheridan APC, Meyers PA, Jacobson N, Winchester RJ. Continuous human bone marrow culture: Ia antigen characterization of probable pluripotential stem cells. *Blood* 1980; 55: 682.

Morley A, Blake J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. *Blood* 1974; 44: 49.

Morley A, Trainor K, Blake JA. A primary stem cell lesion in experimental chronic hypoplastic marrow failure. *Blood* 1975; 45: 681.

Morris PJ. The impact of Cyclosporin-A on transplantation. *Adv Surg* 1984; 17: 99.

Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. *Embo J* 1982; 1: 841.

Oi VT, Jones PP, Goding JW, Herzenberg LA. Properties of monoclonal antibodies to mouse Ig allotypes, H-2 and Ia antigens. *Curr Top Microbiol Immunol* 1979; 81: 115.

Okada S, Palathumpat V, Strober S. Identification of donor-derived antigen-specific suppressor cells in murine bone marrow chimeras prepared with

total-lymphoid-irradiation. *Transplantation* 1983; 36: 417.

O'Neill HC. Heterogeneity among H-2K^k antigens. *Transplantation* 1984; 38: 182.

O'Reilly RJ, Kapoor N, Kirkpatrick D, Cunningham-Rundles S, Pollack MS, Dupont B, Hodes MZ, Good RA, Reisner Y. Transplantation for severe combined immunodeficiency using histoincompatible parental marrow fractionation by soybean agglutinin and sheep red blood cells: Experience in six consecutive cases. *Transplant Proc* 1983; 15: 1431.

Oseroff A, Okada S, Strober S. Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype. *J Immunol* 1984; 132: 101.

Pahwa R, Pahwa S, O'Reilly R, Good RA. Treatment of the immunodeficiency diseases - Progress toward replacement therapy emphasizing cellular and macromolecular engineering. *Springer Semin Immunopath* 1978; 1: 355.

Pals ST, Radaszkiewicz T, Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-versus-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD. *J Immunol* 1984a; 132: 1669.

Pals ST, Gleichmann H, Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-versus-host disease. V. F₁ mice with secondary chronic GVHD contain F₁-reactive allohelper but no allosuppressor T cells. *J Exp Med* 1984b; 159: 508.

Park BH, Biggar WD, Good RA. Minnesota experience in bone-marrow transplantation in man, 1968 to June 1973. *Transplant Proc* 1974; 6: 379.

Parr EL, Kirby WN. An immunoferritin labeling study of H-2 antigens on dissociated epithelial cells. *J Histochem Cytochem* 1979; 27: 1327.

Paul WE. In: *Fundamental Immunology*. Raven Press. 1984: p 394.

Peeg DE. Bone marrow transplantation. *Lloyd Luke* London 1960.

Peterson AC, Flair PM, Wong GG. A technique for detection of glucosephosphate isomerase isozymes from nanogram tissue samples. *Biochem Genet* 1978; 16: 681.

- Pluznik DH, Sachs L. The cloning of normal 'mast' cells in tissue culture. *J Cell Comp Physiol* 1965; 66: 319.
- Pollack SB, Tan MR, Nowinski RC, Emmons SL. Presence of T cell-associated surface antigens on murine NK cells. *J Immunol* 1979; 123: 1818.
- Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G, Hoffbrand AV. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukemia. *Lancet* 1982; 8274: 700.
- Pritchard LL, Halle-Pannenko O. Interactions of major and minor histocompatibility antigens in the graft-versus-host reaction. *Transplantation* 1981; 31: 257.
- Raghupathy R, Singh B, Barrington-Leigh J, Wegmann TG. The ontogeny and turnover kinetics of parental H-2K antigenic determinants on the allogeneic murine placenta. *J Immunol* 1981; 127: 2074.
- Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. *Am Rev Respir Dis* 1984; 129: 641.
- Ramsay NKC, Kim T, Nesbit ME, Krivit W, Coccia PF, Levitt SH, Woods WG, Kersey JA. Total lymphoid irradiation and cyclophosphamide as preparation for bone-marrow transplantation in severe aplastic anemia. *Blood* 1980; 55: 344.
- Rappaport H, Khalil A, Halle-Panneko O, Pritchard L, Dantchev D, Mathe G. Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers. *Am J Pathol* 1979; 96: 121.
- Rappard-van der Veen FM van, Radaszkiewicz T, Terraneo L, Gleichmann E. Attempts at standardization of lupus-like graft-versus-host disease: Inadvertent repopulation by DBA/2 spleen cells of H-2 different nonirradiated F₁ mice. *J Immunol* 1983; 130: 2693.
- Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. *Blood* 1983; 61: 341.

- Remlinger K, Martin PJ, Hansen JA, Doney KC, Smith A, Deeg HJ, Sullivan K, Storb R, Thomas ED. Murine monoclonal anti-T-cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. *Hum Immunol* 1984; 9: 21.
- Ringden O, Lonnquist B, Lundgren G, Gahrton G, Groth C-G, Moller E, Baryd I, Johansson B, Philstedt P, Gullbring B. Experience in the cooperative bone marrow transplantation program in Stockholm. *Transplantation* 1982; 33: 500.
- Risser R, Horowitz JM, McCubrey J. Endogenous mouse leukemia viruses. *Annu Rev Genet* 1983; 17: 85.
- Rodt H, Thierfelder S, Eulitz M. Anti-lymphocytic antibodies and marrow transplantation: 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice. *Eur J Immunol* 1974; 4: 15.
- Rolink AG, Radaszkiewicz T, Pals ST, Van der Meer WGJ, Gleichmann E. Allosuppressor and allohelper T-cells in acute and chronic graft-versus-host disease. I. Alloreactive suppressor cells rather than killer T-cells appear to be the decisive effector cells in lethal graft-versus-host disease. *J Exp Med* 1982; 155: 1501.
- Rolink AG, Pals ST, Gleichmann E. Allosuppressor and allohelper T-cells in acute and chronic graft-versus-host disease. II. F₁ recipients carrying mutations at H-2K and/or I-A. *J Exp Med* 1983a; 157: 755.
- Rolink AG, Gleichmann E. Allosuppressor and allohelper T-cells in acute and chronic graft-versus-host disease. III. Different Lyt subsets of donor T-cells induce different pathological syndromes. *J Exp Med* 1983b; 158: 546.
- Rubin BA. Tolerance to skin homografts in adult mice after parabiosis. *Nature* 1959; 184: 205.
- Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. *Am J Pathol* 1977; 89: 621.
- Sale GE, Shulman HM, McDonald GB, Thomas ED. Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. *Am J Surg Pathol* 1979; 3: 291.
- Santos GW, Owens AH. Allogeneic marrow transplants in cyclophosphamide treated mice. *Transplant Proc* 1969; 1: 44.

- Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: Preclinical model of aplastic anemia. *J Nat Can Inst* 1974; 53: 1781.
- Santos GW, Elfenbein GJ, Tutschka PJ. Bone marrow transplantation - present status. *Transplantation Proc* 1979; XI: 182.
- Saurat JH, Didier-Jean L, Gluckman E, Bussel A. Graft-versus-host reaction and lichen planus-like eruption in man. *Br J Dermatol* 1975; 93: 591.
- Schofield R. The relationship between the spleen colonyforming cell and the hemopoietic stem cell: a hypothesis. *Blood Cells* 1978; 4: 7.
- Sensenbrenner LL, Beale M, Elfenbein, Santos GW. Cloning isologous, allogeneic, and xenogeneic bone marrow cells in the spleens of drug-treated mice. Biology Division. Oak Ridge National Laboratory. *Exper Hemat* 1968; 15: 85.
- Shaw AR, Berko B, Wegmann TG. Immunological tolerance: Dissociation between *in vivo* and *in vitro* reactivity in parabiosed mice. *J Exp Med* 1974; 139: 767.
- Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. *Am J Med* 1980; 69: 204.
- Simonsen M. Graft-versus-host reactions. Their natural history, and applicability as tools of research. *Prog Allergy* 1962; 6: 349.
- Sinclair WH. Hydroxyurea effect on chinese hamster cells grown in culture. *Cancer Res* 1967; 27: 297.
- Singer A, Hathcock KS, Hodes RJ. Cellular and genetic control of antibody response. V. Helper T cell recognition of H-2 determinants on accessory cells but not B cells. *J Exp Med* 1979; 149: 1208.
- Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, Goldberg SZ, Anderson WF, Barnett LB, Lewis SE. A mouse model for beta-thalassemia. *Cell* 1983; 34: 1043.
- Slavin S, Strober S, Fuk Z, Kaplan HS. Induction of specific tissue transplantation tolerance by using fractionated total lymphoid irradiation in adult mice: Long-term survival of allogeneic bone marrow and skin grafts. *J Exp Med* 1977; 146: 43.

- Slavin S, Fuks Z, Strober S, Kaplan HS, Howard R, Sutherland DER. Overview: Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation. *Transplantation* 1979a; 28: 359.
- Slavin S, Strober S. Induction of allograft tolerance after total lymphoid irradiation (TLI): Development of suppressor cells of the mixed leukocyte reaction (MLR). *J Immunol* 1979b; 123: 942.
- Slavin S, Zan-Bar I, Strober S. Generation of protein-specific and alloantigen-specific suppressor cells following total lymphoid irradiation in mice. *Transplant Proc* 1979b; 11: 891.
- Slavin S, Seidel HJ. Hemopoietic activity in bone marrow chimeras prepared with total lymphoid irradiation (TLI). *Exp Hematol* 1982; 10: 206.
- Snell, GD, Dausset J, Nathenson S. Allogeneic cell interactions uniquely dependent on H-2. In: Histocompatibility. *Academic Press* New York 1976: p 156.
- Solberg CO, Matsen JM, Vesley D, Wheeler DJ, Good RA, Meuwissen HJ. Laminar airflow protection in bone marrow transplantation. *Appl Microbiol* 1971; 21: 209.
- Sondel PM, Trigg ME, Finlay JL, Bozdech MJ. Pediatric bone marrow transplantation: current progress and future prospects. *Pediatrics* 1983; 72: 818.
- Sponcer E, Gallagher J, Dexter TM. Glycosaminoglycans of haemopoiesis in vitro. *Carbohydr Res* 1981; 87: 127.
- Sprent J, Miller JFAP. Interaction of thymus lymphocytes with histoincompatible cells. I. Quantitation of the proliferative response of thymus cells. *Cellular Immunol* 1972; 3: 361.
- Sprent J, von Boehmer H. T helper function of parent $\rightarrow$ F₁ chimeras. Presence of separate T cell subgroups able to stimulate allogeneic B cells but not syngeneic B cells. *J Exp Med* 1979; 149: 387.
- Storb R, Rudolph RH, Kolb HJ, Graham TC, Mickelson E, Erickson V, Lerner KG, Kolb H, Thomas ED. Marrow grafts between DLA matched canine littermates. *Transplantation* 1973; 15: 92.
- Storb R, Weiden PL, Schroeder ML, Graham TC, Lerner KG, Thomas ED. Marrow grafts between canine littermates homozygous or heterozygous for lymphocyte-defined histocompatibility antigens. *Transplantation* 1976 ; 21: 299.

Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. *N Engl J Med* 1977; 296: 61.

Storb R, Thomas ED, Buckner ED, Clift RA, Deeg HJ, Fefer A, Goodell BW, Sale GE, Sanders JE, Singer J, Stewart P, Weiden PL. *Ann Intern Med* 1980; 92: 30.

Storb R, Doney KC, Thomas ED, Appelbaum F, Buckner CD, Clift RA, Deeg HJ, Goodell BW, Hackman R, Hansen JA, Sanders J, Sullivan K, Weiden PL, Witherspoon RP. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. *Blood* 1982a; 59: 236.

Storb R, Deeg HJ, Atkinson K, Weiden PL, Sale G, Colby R, Thomas ED. Cyclosporin-A abrogates transfusion-induced sensitization and prevents marrow graft rejection in DLA-identical canine littermates. *Blood* 1982b; 60: 524.

Storb R, Thomas ED. Allogeneic bone-marrow transplantation. *Immunological Rev* 1983a; 71: 77.

Storb R, Prentice RL, Witherspoon RP, Sullivan KM, Stewart PS, Sanders JE, Mason M, Doney KL, Deeg HJ, Clift RA, Buckner CD, Appelbaum FA, Thomas ED. Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia. Is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment? *Blood* 1983b; 61: 672.

Storb R, Prentice RL, Sullivan KM, Schulman HM, Deeg HJ, Doney KC, Buckner CD, Clift RA, Witherspoon RP, Appelbaum FA, Sander JE, Stewart PS, Thomas ED. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. *Ann Intern Med* 1983c; 98: 461.

Storb R. Pathophysiology and prevention of graft-versus-host disease. In: *Advances in Immunobiology: Blood Cell Antigens and Bone Marrow Transplantation*. Allan R Liss 1984: p 337.

Strober S, Slavin S, Gottlieb H, Zan-Bar I, King DP, Hoppe RT, Fuks Z, Grumet FC, Kaplan HS. Allograft tolerance after total lymphoid irradiation (TLI). *Immunol Rev* 1979; 46: 87.

Strober S. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation. *Ann Rev*

Immunol 1984; 2: 219.

Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. *Blood* 1981; 57: 267.

Sullivan KM, Deeg HJ, Sanders JE, Shulman HM, Witherspoon RP, Doney K, Applebaum FR, Schubert MM, Stewart P, Springmeyer S, McDonald GB, Storb R, Thomas ED. Late complications after marrow transplantation. *Semin Hematol* 1984; 21: 53.

Tada T. Help, suppression and specific factors. In: Fundamental Immunology. Paul W (ed). *Raven Press*, New York, 1984: c 18, p 481.

Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone marrow transplantation. *N Engl J Med* 1975; 292: 832.

Thomas ED, Flournoy N, Buckner CD, Clift RA, Fefer A, Neiman PE, Storb R. Cure of leukemia by marrow transplantation. *Leuk Res* 1977a; 1: 67.

Thomas ED, Flournoy N, Buckner CD, Clift RA, Fefer A, Neiman PE, Storb R. *Leuk Res* 1977b; 1: 67.

Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb R, Weiden PL. Marrow transplantation for acute, non-lymphoblastic leukemia in first remission. *N Engl J Med* 1979; 301: 597.

Thomas ED, Buckner CD, Sanders J, Papayannopoulou T, Borgna-Pignatelli C, DeStefano P, Sullivan KM, Clift RA, Storb R. Marrow transplantation for thalassemia. *Lancet* 1982; 2: 227.

Thomas ED, Clift RA, Storb R. Indications for marrow transplantation. *Ann Rev Med* 1984; 35: 1.

Thompson J, van Furth R. The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. *J Exp Med* 1970; 131: 429.

Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 1961; 14: 213.

Trentin JJ. Influence of hematopoietic organ stroma (hematopoietic inductive microenvironments) on stem cell differentiation. In: Regulation of Hematopoiesis, Vol 1.

- ed Gordon AS. Appleton-Century-Crofts, New York 1970. p 161.
- Trentin JJ. Hemopoietic microenvironments. *Transplant Proc* 1978; 10: 77.
- Tsoi MS. Immunological mechanisms of graft-versus-host disease in man. *Transplantation* 1982; 33: 459.
- Tsoi MS, Storb R, Thomas ED. Immunological basis of graft-versus-host disease in humans. In: Recent Advances in Bone Marrow Transplantation. *Allan R Liss* New York 1983: p 291.
- Tutschka PJ and Santos GW. Bone marrow transplantation in the busulfan-treated rat. *Transplantation* 1977; 24: 52.
- Udupa KB, Okamura H, Reissmann KR. Granulopoiesis during Myleran induced suppression of transplantable hematopoietic stem cells. *Blood* 1972; 39: 317.
- Uphoff DE. Preclusion of secondary phase of irradiation syndrome by inoculation of fetal hematopoietic tissue following lethal total-body X irradiation. *J Natl Cancer Inst* 1958; 20: 625.
- Vallera DA, Soderling CCB, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice: II. T cell requirement for engraftment in total lymphoid irradiation-conditioned recipients. *Transplantation* 1982; 33: 243.
- Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PC, Neville DM Jr, Youle RJ. Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. *Science* 1983; 222: 512.
- van Bekkum DW, de Vries MJ. Radiation chimeras. *Logos Press* 1967.
- van Bekkum DW, Wagemaker G, Vriesendorp HM. Mechanisms and avoidance of graft-versus-host disease. *Transplant Proc* 1979; 1: 189.
- van Bekkum DW. Immunological basis of graft-versus-host disease. In: Biology of bone marrow transplantation - ICN-UCLA Symposium on molecular and cellular biology. Gale RP and Fox CF(eds) *Academic Press* 1980: p 175.
- Van Elven EH, Rolink AG, VanderVeen F, Gleichman E. Capacity of genetically different T lymphocytes to induce lethal graft-versus-host disease correlates with their capacity to generate suppression but not their capacity to

generate anti-F, killer cells. A non-H-2 locus determines the inability to induce lethal graft-versus-host disease. *J Exp Med* 1981; 153: 1474.

Van Ewijk W. Immunolectron-microscopic characterization of lymphoid microenvironments in the lymph node and thymus. *Ciba Found Symp* 1980; 71: 21.

van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. *J Exp Med* 1968; 128: 415.

van Furth R, Hirsch JG, Fedorko ME. Morphology and peroxidase cytochemistry of mouse promonocytes, monocytes and macrophages. *J Exp Med* 1970; 132: 794.

Van Zant G. Studies of hematopoietic stem cells spared by 5-flurouracil. *J Exp Med* 1984; 159: 679.

von Boehmer H, Sprent J, Nabholz M. Tolerance to histocompatibility determinants in tetraparental bone marrow chimeras. *J Exp Med* 1975a; 141: 322.

von Boehmer H, Hudson L, Sprent J. Collaboration of histoincompatible T and B lymphocytes using cells from tetraparental bone marrow chimeras. *J Exp Med* 1975b; 142: 989.

Waer M, Ang KK, van der Schueren E, Vandeputte M. Allogeneic bone marrow transplantation in mice after total lymphoid irradiation: influence of breeding conditions and strain of recipient mice. *J Immunol* 1984; 132: 991.

Waldmann H, Pope H, Brent L, Bighouse K. Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation. *Nature* 1978; 274: 166.

Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). *Lancet* 1984; 8401: 483.

Waldor MK, Hardy RR, Hayakawa K, Steinman L, Herzenberg LA, Herzenberg LA. Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. *Proc Nat Acad Sci, USA* 1984; 81: 2855.

Warner JF, Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metasis in vivo. *Nature* 1982; 300: 31.

Wegmann TG, Rosovsky J, Carlson GA, Diener E, Drell DW.

- Models for the production of stable hemopoietic chimerism across major histocompatibility barriers in adults. *J Immunol* 1980; 125: 1751.
- Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. *N Engl J Med* 1979; 300: 1068.
- Weiden PL and the Seattle Marrow Transplant Team. Graft-versus-host disease in allogeneic marrow transplantation. In: Biology of bone-marrow transplantation - ICN-UCLA Symposium on Molecular and Cellular Biology. Gale RP, Fox CF (eds). *Academic Press* 1980: p 37.
- Weinbeck J. Die granulopese des kindlichen knochenmarkes und ihre reaktion auf infectionen. *Beitrage Pathologischen Anatomie und zur Allgemeinen Pathologie*. 1938; 101: 268. Cited in Lord BI, 1983.
- Weiss L. The haemopoietic microenvironment of bone marrow: an ultrastructural study of the interactions of blood cells, stroma and blood vessels. In: Blood Cells and Vessel Walls: Functional Interactions. Elsevier/North Holland: CIBA Foundation Series 1980; 71: 3.
- Wigler M, Silverstein S, Lee L-S, Pellicer A, Cheng Y-C, Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. *Cell* 1977; 11: 223..
- Williams DA, Lemischka IR, Nathan DG, Mulligan RC. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. *Nature* 1984; 310: 476.
- Winston DJ, Ho WG, Champlin RE, Gale RP. Infectious complications of bone marrow transplantation. *Exp Hematol* 1984; 12: 205.
- Witherspoon RP, Deeg HJ, Lum LG, Ochs HD, Hansen JA, Thomas ED, Storb R. Immunologic recovery in human marrow graft recipients given cyclosporin or methotrexate for the prevention of graft-versus-host disease. *Transplantation* 1984a; 37: 456.
- Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after marrow grafting. *Semin Hematol* 1984b; 21: 2.
- Wolf NS, Trentin JJ. Hemopoietic colony studies. *J Exp Med* 1968; 127: 205.
- Worton RG, McCulloch EA, Till JE. Physical separation of

hemopoietic stem cells from cells forming colonies in culture. *J Cell Physiol* 1969; 74: 171.

Xu CX, Hendry JH. The radial distribution of fibroblastic colony-forming cells in mouse femoral marrow. *J Rad Biol* 1981; 35: 119.

Yeager AM, Brennan S, Tiffany C, Moser HW, Santos GW. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. *Science* 1984; 225: 1052.

Zinkernagel RM, Callahan GN, Althage A, Cooper S, Klein PA, Klein J. On the thymus in the differentiation of "H-2 self recognition" by T cells: evidence for dual recognition? *J Exp Med* 1978; 147: 882.

Zucker-Franklin D, Greaves MF, Grossi CE, Marmot AM. In: Atlas of Blood Cells - Function & Pathology. Lea & Febiger, Philadelphia 1981.

Vita

Name: Louis Hugo Francescutti.
Place of Birth: Montreal, Quebec.
Year of Birth: 1953.

POST-SECONDARY EDUCATION and DEGREES:

Concordia University,
Montreal, Quebec.
1977 - 1980, B.Sc. (Honours Biology).

University of Alberta,
Edmonton, Alberta.
1980 - 1985, Ph.D. (Medical Sciences).

HONOURS and AWARDS:

Loyola Campus Medal,
Concordia University, Montreal.
1980.

Studentship Award,
Alberta Heritage Foundation for Medical Research.
1980 - 1984.

Publications

Francescutti LH, Gambel P, Wegmann TG. Injection chimeras: A model for the production of complete hemopoietic takeover in histoincompatible adults. *Transplant Proc* 1983; XV: 1477.

Gambel, Francescutti LH, Wegmann TG. Antibody-Facilitated Chimeras: Stem cell allotransplantation using antihost major histocompatibility complex monoclonal antibodies instead of lethal irradiation for host conditioning. *Transplantation* 1984; 38: 152.

McCarthy SA, Francescutti LH, Gambel P, Griffith JJ, Semeluk A, Diener E, Wegmann TG. Identification of host lymphoid cells in Antibody-Facilitated Bone Marrow Chimeras. *Transplant Proc* 1985; XVII: 510.

Francescutti LH, Gambel P, Wegmann TG. Characterization of hemopoietic stem cell chimerism in Antibody-Facilitated Chimeras. *Transplantation* 1985; in press.

McCarthy SA, Griffith IJ, Gambel P, Francescutti LH, Wegmann TG. Characterization of host lymphoid cells in Antibody-Facilitated Bone Marrow Chimeras. *Transplantation* 1985; in press.

McCarthy SA, Griffith IJ, Gambel P, Fotedar A, Francescutti LH, Wegmann TG. Immunological competence of Antibody-Facilitated Bone Marrow Chimeras. Submitted for publication, 1984.

McCarthy SA, Gambel P, Francescutti LH, Diener E, Wegmann TG. Host-specific tolerance in Antibody-Facilitated Bone Marrow Chimeras. Submitted for publication, 1984.